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ABSTRACT 
 
Chronic gastrointestinal disease in dogs can manifest itself in many different ways 
including vomiting, diarrhea, and weight loss. Bile acid dysmetabolism has recently been 
recognized as an important component of chronic gastrointestinal disease (e.g., Crohn’s 
disease, Ulcerative Colitis, Irritable Bowel Syndrome, and Inflammatory Bowel Disease) 
in humans. The aim of this research was to evaluate bile acid dysmetabolism in chronic 
enteropathy of dogs.  
An assay for the measurement of unconjugated fecal bile acids using gas 
chromatography coupled with mass spectrometry was developed. The assay was accurate 
and reproducible. The percent of unconjugated secondary bile acids were significantly 
decreased in dogs with chronic enteropathy (p=0.0161), with approximately 60% of dogs 
having bile acid dysmetabolism. The percent of unconjugated secondary bile acids 
significantly increased in patients with chronic enteropathy after steroid therapy 
(p=0.0183). The effect of cholestyramine, a bile acid sequestrant, was evaluated for the 
ability to alter the fecal bile acid pool in healthy dogs. The concentration of secondary bile 
acids significantly increased in feces of healthy dogs administered cholestyramine 
(p=0.0183).  These results demonstrate that a subset of dogs with chronic enteropathy 
show fecal bile acid dysmetabolism, and further studies are warranted to evaluate the use 
of bile acid sequestrants in clinical cases. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW* 
Recent molecular studies have revealed a complex microbiota in the dog intestine. 
Convincing evidence has been reported linking changes in microbial communities to acute 
and chronic gastrointestinal inflammation, especially in canine inflammatory bowel 
disease (IBD). The most common microbial changes observed in intestinal inflammation 
are a decrease in the bacterial phyla Firmicutes (i.e., Lachnospiraceae, Ruminococcaceae, 
and Faecalibacterium) and Bacteroidetes, with a concurrent increase in Proteobacteria 
(i.e., E. coli). Due to the important role of microbial-derived metabolites for host health, 
it is important to elucidate the metabolic consequences of gastrointestinal dysbiosis. 
Metagenomic studies have utilized shotgun sequencing of DNA as well as PICRUSt 
(Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) to 
characterize functional changes in the bacterial metagenome in GI disease. Untargeted 
measurements of metabolic products derived by the host and the microbiota continue to 
better describe functional alterations that occur in gastrointestinal disease. For example, 
changes in bile acid metabolism and tryptophan catabolism have recently been reported in 
humans and dogs with GI disease. Metabolites associated with the pentose phosphate 
pathway were significantly altered in chronic GI inflammation, indicating the presence of 
oxidative stress in dogs with IBD.  
                                                 
* Part of the data reported in this chapter is reprinted with permission from the Journal of Animal Science 
by Guard, B. C., and J. S. Suchodolski. "HORSE SPECIES SYMPOSIUM: Canine intestinal 
microbiology and metagenomics: From phylogeny to function." Journal of animal science 94.6 (2016): 
2247-2261. 
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Our understanding of the canine gastrointestinal microbiota during health and 
disease has increased drastically over the past decade, however, major hurdles, such as 
understanding the function of microbes, still exist. Metabolomics measures the collective 
activity of metabolites in the GI tract. Additionally, metabolomics can identify actual 
alterations in the GI ecosystem and can be reflective of real time bacterial and host by-
products. This approach helps to answer the question of ‘what are microbes actively 
doing?’ This functional capacity may be similar between dogs and humans (i.e., functional 
core). The functional core is made up of important host-microbial end products, such as 
complex polysaccharide degradation, as well as the synthesis of short-chain fatty acids, 
amino acids, and vitamins (Turnbaugh et al., 2009; Qin et al., 2010; Swanson et al., 2011).  
The microbiota in healthy dogs and dogs with GI disease 
The complex interactions that exist between GI microbes and the canine host are 
critical for immune regulation, nutrient metabolism, and various other physiological 
processes (Amtsberg et al., 1978; Swanson et al., 2002; Satyaraj et al., 2013; Kainulainen 
et al., 2015). Over the past decade, a combination of culture-based methods coupled with 
next-generation sequencing has provided a thorough overview of the phylogenetic 
composition that makes up the intestinal microbial community in dogs (Suchodolski et al., 
2009; Middelbos et al., 2010; Garcia-Mazcorro et al., 2011; Handl et al., 2011; Garcia-
Mazcorro et al., 2012). The mammalian intestine is home to a total of 1010 to 1014 microbial 
cells, which is approximately 10 fold more than the number of host cells.  The GI 
microbiota plays a critical role in host health. This is achieved by establishing a first line 
of defense against pathogens, aiding in energy harvest and digestion, supporting 
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enterocyte nutrition, and bolstering the immune system (Swanson et al., 2011). Nutritional 
benefits of gut microbes include the digestion of complex carbohydrates to produce short 
chain fatty acids (SCFA, i.e., acetate, propionate, and butyrate), which promote intestinal 
health (Roediger, 1982). It has become evident that the gastrointestinal microbiota also 
plays a role in disease. Alterations in the composition of the microbiota have now been 
well documented in dogs with chronic enteropathy (CE) and dogs with acute diarrhea 
(Suchodolski et al., 2012a; Suchodolski et al., 2012b; Minamoto et al., 2014b; Guard et 
al., 2015). Similar changes have been noted in humans with IBD, such as Crohn’s disease 
and ulcerative colitis (Frank et al., 2007; Dethlefsen et al., 2008; Packey and Sartor, 2009). 
These studies suggest that the microbial response is conserved across mammalian species 
during inflammatory conditions. Therefore, dogs may serve as a useful model for 
inflammatory conditions of the gastrointestinal tract in humans. 
In healthy dogs, initial studies using traditional bacterial culture methodology 
estimated that the bacterial load in the small intestine of dogs ranged from 102 to 109 cfu/g 
of small intestinal contents (German et al., 2003). In the colon the number of  bacteria 
ranges from 108 to 1011 cfu/g (Mentula et al., 2005). High-throughput sequencing studies 
have shown that the predominant phyla in the feces of healthy dogs are Bacteroidetes, 
Firmicutes, Fusobacteria, and Proteobacteria (Handl et al., 2011; Igarashi et al., 2014; 
Guard et al., 2015). Less abundant phyla (less than 1%) are Spirochaetes, Tenericutes, 
Verrucomicrobia, and TM7 (Candidatus Saccharibacteria) in healthy dogs (Suchodolski, 
2011). The GI microbiota of dogs is similar to humans, where  Firmicutes, Bacteroidetes 
and Actinobacteria also constitute the major bacterial phyla (Consortium, 2012). 
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In contrast, the phylogenetic composition of the GI microbiota in dogs with GI 
disease is distinctly different from that of healthy dogs. Chronic enteropathies can be 
categorized by how a patient responds to treatment (e.g., antibiotic responsive, food 
responsive, or steroid responsive diarrhea). IBD in dogs is characterized by confirmed 
inflammation upon histopathological evaluation of GI tissue, similarly, this diagnosis can 
be categorized by how a patient response to treatment as mentioned previously. 
Microbiota alterations in patients with GI disease vary depending on the sampling site. In 
the duodenum of dogs with IBD, bacterial groups belonging to Fusobacteria, 
Bacteroidaceae, Prevotellaceae, and Clostridiales are underrepresented while the bacterial 
genera (within Proteobacteria) Diaphorobacter and Acinetobacter are overrepresented 
(Suchodolski et al., 2012a). The changes in fecal microbiota in dogs with IBD are, to some 
extent, similar to changes observed in the duodenal microbiota of dogs with IBD, with 
members of Proteobacteria being increased (i.e., Gammaproteobacteria) (Minamoto et al., 
2014b). The same study identified a decrease in fecal bacterial groups belonging to 
Erysipelotrichia, Clostridia, and Bacteroidia. A decrease in the abundance of 
Faecalibacterium and the phylum Fusobacteria has also been identified in the fecal 
microbiota of dogs with IBD (Suchodolski et al., 2012b). Decreased abundances of 
Faecalibacterium, Clostridia, Erysipelotrichia in dogs with IBD may be detrimental to the 
production of SCFA, which as discussed previously, can significantly influence host 
health. Minamoto et al. (2014b) reported that compared with healthy dogs, microbial 
communities were altered in dogs with IBD before treatment (n = 12), but did not cluster 
with the microbial communities belonging to healthy dogs post-treatment. In patients with 
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Crohn’s disease, the bacterial phyla Firmicutes and Bacteroidetes are consistently 
decreased with a concurrent increase in Proteobacteria (Sokol et al., 2008; Frank et al., 
2011). Since the depletion of commensal bacterial groups seems to be apparent in dogs 
with chronic GI disease, it may be reasonable to counterbalance intestinal dysbiosis with 
beneficial bacterial species (i.e., probiotics) (Rossi et al., 2014). 
 Infectious organisms may cause acute diarrhea.  (e.g., Camplyobacter jejuni, 
Salmonella, Clostridium perfringens) (Cave et al., 2002; Unterer et al., 2011). Dogs with 
acute diarrhea experience major shifts in their fecal microbial community compared with 
healthy dogs (Suchodolski et al., 2012b; Guard et al., 2015). This is characterized by a 
decrease in Blautia, Faecalibacterium, Ruminococcaceae, and Turicibacter coupled with 
an increased abundance of Clostridium perfringens. Many of the bacterial groups 
decreased during acute diarrhea are also thought to be producers of SCFA. Decreased 
abundances of Ruminococcaceae and Faecalibacterium were correlated with decreased 
fecal propionate and inversely correlated with fecal butyrate concentrations in dogs with 
acute diarrhea (Guard et al., 2015). A recent study found a correlation between increased 
abundance of Faecalibacterium and improvement of clinical activity index, which may 
indicate that this bacterium can be used to monitor  recovery from GI disease (Rossi et al., 
2014). Profound alterations in microbial communities have been noted in dogs with acute 
diarrhea, necessitating further investigation into the role these microbes play in the GI 
tract. Table 1 summarizes results from various studies highlighting microbial alterations 
in canine health and disease. 
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Table 1. Summary of microbial alterations in dog with various GI diseases. 
Study  Sample site  Presentation (sample size)1  Sequencing method  Bacterial groups increased2,4  Bacterial groups decreased2,3,4 
(Minamoto et al., 2014b)  Feces  Controls (n = 12),  
IBD (n = 12) 
454‐pyrosequencing/qPCR  Enterobacteriaceae, 
Gammaproteobacteria, 
Proteobacteria, 
Escherichia, 
Enterococcus 
Coprobacillaceae, 
Lachnospiraceae, 
Collinsella, 
Erysipelotrichales, 
Coriobacteriales, 
Prevotella, 
Ruminococcaceae 
 
(Guard et al., 2015)  Feces  Controls (n = 13),  
Acute Diarrhea (n = 13) 
454‐pyrosequencing/qPCR  Clostridium perfringens  Bacteroidetes (2.1), 
Faecalibacterium (15.0), 
Unclass. Ruminococcaceae, 
Unclass. Lachnospiraceae (2.9), 
Eubacterium (10.0), 
Blautia (3.9), 
Prevotella 
 
(Rossi et al., 2014)  Feces  Controls (n = 10),  
IBD (n = 20) 
qPCR  None Reported  Faecalibacterium, 
Turicibacter 
 
(Xu et al., 2014)  Feces  Controls (n = 11),  
IBD (n = 23) 
 
DGGE/qPCR  None Reported  Lactobacillus 
(Minamoto et al., 2014a)  Feces  Controls (n = 95), 
GI disease (n = 104) 
qPCR Bifidobacterium,
Lactobacillus, 
E. coli 
Fusobacteria,
Ruminococcaceae, 
Blautia, 
Faecalibacterium 
   
(Markel, 2012)  Feces  Controls (n = 242),  
CE (n = 118),  
Acute Hemorrhagic Diarrhea 
(AHD) (n = 57) 
qPCR  CE 
Lactobacillus, 
Streptococcus 
AHD 
Clostridium perfringens, 
E. coli 
CE 
Bacteroidetes 
AHD 
Lactobacillus, 
Streptococcus, 
Firmicutes 
 
(Jia et al., 2010)  Feces  Controls (n = 8), 
Chronic Diarrhea (n = 9) 
 
FISH Bacteroides None Reported
           
 7 
 
Table 1. Continued. 
Study  Sample site  Presentation (sample size)1  Sequencing method  Bacterial groups increased2,4  Bacterial groups decreased2,3,4 
(Suchodolski et al., 2012a)  Duodenum  Controls (n = 6),  
IBD (n = 14) 
454‐pyrosequencing  Proteobacteria (2.3), 
Diaphorobacter, 
Acinetobacter 
Fusobacteria (29.6), 
Bacteroidaceae, 
Prevotellaceae, 
Clostridiales 
 
(Suchodolski et al., 2012b)  Feces  Controls (n = 32), 
Acute Non‐Hemorrhagic 
Diarrhea (n = 12),  
Acute Hemorrhagic Diarrhea 
(n = 13),  
Active IBD (n = 9),  
Therapeutically Controlled 
IBD (n = 10) 
454‐pyrosequencing/qPCR  AHD
Sutterella, 
Clostridium perfringens 
AHD
Blautia (49.5), 
Ruminococcaceae (20.0), 
Faecalibacterium, 
Turicibacter 
NHD 
Blautia (49.5), 
Ruminococcaceae (3.4), 
Turicibacter (5.0), 
Faecalibacterium, 
Bacteroidetes 
Active IBD 
Faecalibacterium, 
Fusobacteria 
 
(Suchodolski et al., 2010)  Duodenum  Controls (n = 7),  
IBD (n = 7) 
 
Gene Clone Libraries  Proteobacteria  Clostridia 
(Allenspach et al., 2010)  Duodenum  Controls (n = 8),  
CE (n = 13) 
Gene Clone Libraries  Actinobacteria (8.8), 
Lactobacillales, 
Erysipelotrichi 
 
None Reported 
(Xenoulis et al., 2008)  Duodenum  Controls (n = 9),  
IBD (n = 10) 
Gene Clone Libraries  Enterobacteriaceae (29.9), 
E. coli 
None Reported 
1Alterations in bacterial groups are based on comparison to controls or baselines in the related study, unless otherwise noted. 
2Fold changes were calculated and displayed in parenthesis for only studies that compared the percent of total bacteria between groups.  
3In cases where bacterial abundance was decreased the inverse value is provided. 
4Fold changes were not calculated between groups where a “zero” abundance was present and in the absence of raw data provided in the study.  
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Metabolomics in canine gastrointestinal disease 
Metabolomics was introduced in the 1990s, formatted initially for evaluating 
drug toxicity (Nicholson et al., 1999). By definition, metabolomics is the “study of 
metabolites which employs non-biased identification and quantification of all metabolites 
in a biological system” (Ellis et al., 2007). The context of metabolomics in the GI tract 
includes investigating the role of metabolites in various GI disorders and potentially 
elucidating novel biomarkers for the etiology, progression, and treatment of such diseases 
(Walker et al., 2014). This approach is useful in that it can provide non-invasive strategies 
for the prognosis and diagnosis of GI diseases in addition to understanding complex 
metabolic pathways. 
Several different techniques in metabolomics are used to create a metabolic profile. 
Untargeted metabolomics is a technique that unbiasedly profiles metabolites. Because 
inherent instrument limitations exist for the detection of all metabolites, a multitude of 
platforms needs to be used, such as gas chromatography (GC), liquid chromatography 
(LC), mass spectrometry (MS), and nuclear magnetic resonance (NMR) to increase the 
number of qualitative and semi-quantitative results (Weckwerth, 2003). In untargeted 
metabolomics, high-mass accuracy instruments such a GC-Time-Of-Flight (TOF)-MS are 
capable of generating and matching mass spectra to libraries of compounds. Alternatively, 
in targeted metabolomics, unknown samples are compared with pure standard compounds 
for positive identification and quantitation. 
Metabolomics is still in its infancy with little standardization across studies or 
platforms (Kanani et al., 2008). Feces can be a difficult matrix to work with compared 
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with serum and urine, given the large amount of impurities present in a sample. This 
proves to be especially true when working with highly sensitive machines (i.e, GC/MS 
and liquid chromatography/mass spectrometry). There is currently no gold standard for 
normalization of fecal metabolite concentrations (e.g., adjusting by fecal dry weight or 
starting with lyophilized fecal sample). 
 Minamoto et al. (2014b) described for the first time alterations in serum 
metabolites in healthy dogs and dogs with idiopathic IBD (Minamoto et al., 2014b). 
Multivariate analysis of all untargeted serum metabolite concentrations revealed tight 
clustering in healthy dogs while dogs with IBD before treatment were very scattered, 
indicating global variability among metabolite profiles in dogs with IBD. This study 
reported a decreased abundance of amino acids in dogs with IBD, whereas a wide variety 
of metabolites were increased in dogs with IBD according to the heatmap. Predictive 
metagenomics using 16S rRNA genes, indicated that the microbiota in dogs with IBD 
contribute to dysfunctional amino acid metabolism. These results are some of the first of 
its kind in dogs to describe the functional capacity of the metagenome and its function in 
vitro. A link is becoming clearer between amino acids and the pathogenesis of IBD. For 
example, a study in humans measured the plasma amino acid concentrations in 387 IBD 
patients and 210 healthy controls (Hisamatsu et al., 2012). That study reported decreased 
concentrations of histidine and tryptophan in patients with IBD (~72 µM and ~45 µM, 
respectively) compared with healthy controls (~83 µM and ~49 µM, respectively). The 
concentrations of histidine and tryptophan were inversely correlated with the 
inflammatory marker C-reactive protein (r2 = −0.460 and −0.370, respectively; p<0.001 
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for both). Interestingly, the amino acid tryptophan is metabolized into kynurenine by 
indoleamine 2,3-dioxygenase and may act as an immunological regulator (O'connor et al., 
2009). This may provide further evidence of a potential relationship between amino acids 
and inflammation. 
Of the hundreds of serum metabolites measured in the study by Minamoto et al. 
(Minamoto et al., 2014b), only nine were significantly altered. Of those, four metabolites 
were named and five were unnamed. The four identified metabolites included 
gluconolactone, hexuronic acid, 3-hydroxybutanoic acid, and ribose; all which were 
significantly increased in dogs with IBD before treatment (approximate median peak 
intensity = 750, 2,100, 2,100, and 8,500; respectively) compared with healthy control dogs 
(approximate median peak intensity = 300, 1,000, 1,700, and 3,000; respectively). 
Gluconolactone was the only identifiable metabolite that decreased after treatment in dogs 
with IBD (approximate median peak intensity = 450). Gluconolactone is an oxidized 
derivative of glucose and is capable of scavenging free radicals. It may serve as a surrogate 
marker for inflammation given its ability to discriminate between dogs with IBD before 
and after treatment. Metaboanalyst (Xia et al., 2015) (a comprehensive and freely-
available online (http://www.metaboanalyst.ca) tool suite for metabolomics data analysis) 
was used to compare metabolic pathways; the pentose phosphate pathway was more active 
in dogs with IBD, mainly due to an increase in gluconolactone and ribose. The pentose 
phosphate plays a role in redox balance, proliferation, and protection from oxidative stress. 
Alterations of metabolites involved in these pathways may be indicative of the presence 
of oxidative stress during periods of inflammation. Metabolomic profiling in the serum of 
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dogs with IBD is fairly novel and draws major parallels to what is reported in human GI 
disease. The pathogenesis of human IBD is highly complex; therefore, a multitude of 
causes may be at play. These studies further support an inappropriate inflammatory 
response and a variety of metabolic fluctuations that may play a role (Colombel, 2014). 
Reactive oxygen species may contribute to oxidative stress because, in humans, they have 
been found to be increased during active ulcerative colitis and decreased once patients are 
in remission. These changes are also accompanied by decreased antioxidant levels, which 
in a two-fold approach, likely contribute to major pathogenic mechanisms in IBD (Beltran 
et al., 2010; Bhattacharyya et al., 2014). Metabolite alterations in this study add new depth 
to understanding IBD in dogs given that studies in human IBD have largely focused on 
and reported altered lipid and amino acid metabolism (De Preter and Verbeke, 2013). 
Therapeutic intervention in canine gastrointestinal disease 
Studies in mice and humans have pioneered the use of metabolomics and 
metagenomics in characterizing GI disease (Schicho et al., 2012; Zhu and Li, 2012; 
Walker et al., 2014). One study in patients with ulcerative colitis and Crohn’s disease used 
NMR in an untargeted metabolomics approach to evaluate urine metabolites (Stephens et 
al., 2013). That study reported the percent difference of succinate (−77%), trans-aconitate 
(−43%), and citrate (−35%) to be significantly decreased in patients with IBD. These 
metabolites are well-known to be crucial in the tricarboxylic acid (TCA) cycle. Decreased 
energy metabolites, such as those belonging to the TCA cycle, have been shown in another 
study involving the dextran sulfate sodium (DSS)-induced colitis mouse model (Shiomi 
et al., 2011); they found decreased abundances of TCA cycle intermediates as well as 
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glutamine, tryptophan, tyrosine, asparagine, and glycine compared with controls.  
Furthermore, they observed a positive correlation between glutamine and inflammation. 
In addition, that study reported that supplementation of glutamine could reduce colon 
tissue lesions in a dose-dependent fashion. These results indicate a potential usefulness for 
metabolomics as a novel approach to discover therapeutic targets against GI disease. 
Due to the complexity of bacterial and host interactions in the GI tract, a multi 
‘omics’ approach will likely be necessary in the future to fully understand various GI 
diseases. Studies from our laboratory have only recently begun to describe metabolomic 
changes on a large scale (Minamoto et al., 2014b; Guard et al., 2015). These studies have 
used an untargeted metabolomics approach whereby hundreds of metabolites were 
detected and quantified. These studies, however, have only investigated serum and urine 
metabolites while none have investigated fecal metabolites. Feces may contain surrogate 
markers that correspond to various types of GI disease and serve as a non-invasive 
alternative for sample collection. Some preliminary work indicates that feces from dogs 
with CE contain several hundred significantly altered metabolites (Honneffer et al., 
2015a). Analysis of these metabolites has indicated alterations in bile acid metabolism, 
tryptophan metabolism, and the pentose phosphate pathway. 
Tryptophan metabolism is another pathway that has garnered recent attention in 
canine GI disease (Guard et al., 2015; Honneffer et al., 2015a). Minamoto et al. (2014b) 
noted increased serum tryptophan in dogs with IBD (Minamoto et al., 2014b). The 
essential amino acid L-tryptophan is required for the biosynthesis of proteins and is a 
precursor for several biologically important compounds. It can be catabolized by several 
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different pathways; however, one of particular interest is breakdown of tryptophan to 
kynurenine by tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase (IDO). An 
increased kynurenine to tryptophan ratio can indicate increased IDO, which promotes 
immune activation and endogenous interferon-γ formation (Schröcksnadel et al., 2006). 
Thymus cells (T-cell) have before been implicated in the pathogenesis of IBD in humans 
(Rossi et al., 2014; Maeda et al., 2015), and it is known that IDO regulates cell 
proliferation and survival. Studies in human IBD have shown that IDO mRNA is markedly 
increased in colonic biopsies of IBD patients (Wolf et al., 2004). A study mentioned 
previously used an untargeted-targeted metabolomics approach to evaluate the serum and 
urine of dogs with acute diarrhea (Guard et al., 2015). Urine metabolomics in these dogs 
revealed relatively little changes, with 2-methyl indole and 5-methoxy-1H-indole-3-
carbaldehyde being decreased in dogs with acute diarrhea (~median concentration = 25 
and 75 fg/mg of creatinine, respectively) compared with healthy dogs (~median 
concentration = 125 and 125 fg/mg of creatinine, respectively). While little is known about 
these indole-like compounds, this study also found that serum kynurenic acid (a catabolite 
of kynurenine and tryptophan) was decreased in dogs with acute diarrhea compared with 
healthy dogs (~median concentration = 15 and 45 ng/mL, respectively) as well as the ratio 
of tryptophan to kynurenic acid (Guard et al., 2015). It is important to remember that these 
changes occurred in serum and urine metabolites. Tryptophan can be catabolized in a 
number of different ways; one example is enzymatic breakdown of tryptophan by IDO 
into kynurenine, kynurenic acid, quinolinic acid, and xanthurenic acid (Takikawa, 2005). 
During periods of inflammation, cytokine involvement such as interferon-γ, tumor 
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necrosis factor-α, IL-2, IL-6, IL-18, and IL-1β may shift the direction of tryptophan 
metabolism away from end products such as serotonin and indole derivatives towards 
kynurenine and its downstream products (Oxenkrug, 2007). Many studies performed in 
humans over the past decade have pinpointed significant increases in IDO in patients with 
Crohn’s disease. However, the role of IDO overexpression in human IBD can be 
somewhat complicated. For instance, IDO has been shown to exert inhibitory effects on 
T-cell proliferation in vitro and in vivo (Fallarino et al., 2002). In addition, deprivation of 
tryptophan by upregulation of IDO may regulate T-cell survival (Fallarino et al., 2002; 
Mellor et al., 2002; Wolf et al., 2004). It is important to note that alterations in tryptophan 
metabolism may be different depending on biological site sampled. Recent research has 
demonstrated alterations in fecal tryptophan catabolism in dogs with IBD (Honneffer et 
al., 2015a). In this untargeted fecal metabolomics study, several pathways were 
investigated. As opposed to some findings in the human literature, there were no changes 
in kynurenine compounds, hinting at a seemingly normal IDO and tryptophan 2,3-
dioxygenase expression. Fecal serotonin also remained unchanged in both healthy dogs 
and dogs with chronic GI disease. Alternative pathways of tryptophan metabolism, such 
as downstream indole products, may deserve further attention in dogs with IBD. 
Indolepropionate has been shown in models of rodent brain to act as a potent hydroxyl 
radical scavenger (Poeggeler et al., 1999). Therefore, it could be surmised that decreased 
indolepropionate may further exacerbate oxidative stress, which has been reported in dogs 
with chronic GI disease. While the tryptophan pathway in and of itself does not reflect 
dramatic alterations in fecal or serum metabolites in dogs with GI disease, the interplay 
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still remains to be fully understood. The notion that many metabolic disturbances in unison 
contribute to the etiology of the disease gives leverage to the idea of a complex and 
multifactorial process contributing to dogs with chronic GI disease, specifically dogs with 
IBD. 
Bile acid metabolism 
Overview 
Bile is made up of primarily bile acids along with phosphatidylcholine, bilirubin, 
and cholesterol (Russell, 2009). In the human body, bile acids are well-known to play an 
important physiological role in the uptake of lipids and fat-soluble vitamins in the intestine 
(e.g., A, D, E, and K) (Hofmann, 1999; Trauner et al., 2010).  The synthesis, circulation, 
and metabolism of bile acids is highly complex and varies depending on the mammalian 
species. At the core of bile acid metabolism, primary bile acids are synthesized from 
cholesterol and converted to CoA esters and then conjugated with the amino acids glycine 
and taurine (Russell and Setchell, 1992). In humans, glycine is conjugated preferentially 
to taurine in a 3:1 ratio (Sjövall, 1959). In dogs, however, bile acids are primarily 
conjugated with taurine. Primary bile acids generally consist of cholic and 
chenodeoxycholic acid. After synthesis and conjugation, bile acids are released into the 
proximal duodenum to the site of active absorption in the terminal ileum where 
approximately 95% of bile acids are reabsorbed (Scott et al., 1983); additionally they are 
comprised of a basic micellar structure, and it is with mixed micelles that the absorption 
of fat into mucosal cells is facilitated.  
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 Bile acid metabolism is rate limited by the enzyme Cytochrome P450 7A 
(CYP7A1) in the traditional pathway for bile acid synthesis (Chiang, 1998). The gene that 
encodes the enzyme CYP7A1 is regulated in part by a variety of small lipophilic molecules 
that includes steroid and thyroid hormones, cholesterol, and bile acids. CYP7A1 gene 
expression occurs during influx or feeding of cholesterol and is consequentially repressed 
by bile acids as a negative feedback mechanism. Recently, bile acid receptors have 
garnered attention for their role in glucose and energy homeostasis, along with regulation 
of inflammation (Houten et al., 2006).  
Nuclear receptors as well as liver receptors play an integral role in the regulation 
of bile acid metabolism (Russell, 1999). Most recently the liver X receptor alpha and 
farnesoid X receptor (LXRα and FXR, respectively), have been implicated in the feedback 
loops associated with bile acid synthesis (Forman et al., 1995). Both of these receptors are 
abundantly expressed in the liver and when LXRα is knocked out in mice, CYP7A1 
expression is suppressed in response to cholesterol feeding and furthermore results in an 
accumulation of cholesterol (Peet et al., 1998). 
Role of bile acids in diabetes 
  In type-2 diabetes the host is unable to utilize insulin properly. Recently, it has 
been suggested that bile acid metabolism is altered in patients with type 2 diabetes and 
that modification of the enterohepatic production of bile acids can improve glycemic 
control in some patients (Prawitt et al., 2011). The Farnesoid X Receptor (FXR) is a 
nuclear receptor necessary in the regulation of bile acid synthesis (Stanimirov et al., 2012). 
Studies in FXR deficient mice have shown developing signs of insulin resistance and 
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consequentially, further evidence suggests that FXR agonists may reduce blood glucose 
levels in murine models of obesity and diabetes (Zhang et al., 2006; Cipriani et al., 2010). 
Downstream targets of FXR such as the hormones Fibroblast Growth Factor 15 and 19 
(FGF 15 and FGF 19, respectively) have also been implicated in diabetes mellitus. It has 
also been reported that FGF 15 and FGF 19 are capable of suppressing gluconeogenesis 
(Potthoff et al., 2011). Moreover, targeting bile acid metabolism using bile acid 
sequestrants (i.e., colesevelam) was also found to increase glycemic control (Beysen et 
al., 2012). Other promising targets involved in bile acid metabolism are the glucagon-like 
1 peptide (GLP-1) from intestinal L-cells through the activation of membrane receptor 
TGR5 in addition to tauroursodeoxycholic acid which may help improve insulin resistance 
by attenuating endoplasmic reticulum stress (Katsuma et al., 2005; Özcan et al., 2006). 
Secondary bile acids, the microbiota, and host health 
Traditionally, it has been well known that the gut microbiota has profound effects 
on bile acid metabolism largely through the deconjugation, dehydrogenation, and 
dehydroxylation of primary bile acids in the distal small intestine and colon (Ridlon et al., 
2006). This facilitates the production of secondary bile acids, namely lithocholic, 
deoxycholic, and ursodeoxycholic acid (UDCA). Interestingly, the gut microbiota have 
recently been linked to regulating bile acid metabolism through interactions with specific 
bile acid receptors (Sayin et al., 2013a). A study in germ free mice and conventionally 
raised mice identified that the presence of gut microbiota upregulated the expression of 
FXR and its molecular targets (i.e., Fibroblast Growth Factor 15 (FGF15)), compared to 
germ-free mice (Ridlon et al., 2006). In contrast, there was no effect on expression of FXR 
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or its molecular targets in the liver. These findings suggest that the gut microbiota is 
capable only of regulating the activity of FXR in the ileum but not the liver. The same 
study identified that when FXR was knocked out in mice, FGF15 was incapable of being 
expressed in the ileum highlighting the need for FXR in bile acid regulation.  
 Ideal composition of the bile acid profile in the gastrointestinal tract is critical for 
maintaining intestinal health. Pilot data suggests increased secondary bile acids in the 
feces of healthy dogs and decreased secondary bile acids in dogs with inflammatory bowel 
disease (Honneffer et al., 2015b). Studies in humans have described similar findings 
(Weingarden et al., 2014). Table 2 summarizes studies in mammalian systems 
investigating the different roles of bile acids in disease. Presence of secondary bile acids 
(i.e., lithocholic and deoxycholic acid (DCA)) has been linked to not only maintaining a 
healthy gut but to carcinogenesis as well. For example, the anti-inflammatory properties 
of secondary bile acids were described several decades ago when it was recognized that 
chronic cholestasis was associated with immune suppression. This understanding led to 
the discovery that bile acids helped to inhibit the secretion of TNF-α, IL-1β and IL-6 in 
macrophages (Greve et al., 1989). The G-protein-coupled receptor TGR5 was recognized 
as a bile acid specific membrane receptor capable of reducing proinflammatory cytokines 
such as IL-1α, Il-1β, IL-6 and TNF-α. In humans, the gut microbiota produced the 
strongest activator responsible for activating TGR5 and its anti-inflammatory capabilities.  
 Alternatively, secondary bile acids have been implicated as a causative role in 
colorectal carcinogenesis (Nagengast et al., 1995). Studies in humans with colonic 
adenomas have found increased DCA compared to healthy controls. Additionally, studies 
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in mice that were fed DCA reported inflammation, edema, and necrosis in tissue after 
DCA treatment (Wargovich et al., 1983). Lithocholic acid (LCA) has been identified as a 
tumor promoter through inhibition of DNA polymerases (Ogawa et al., 1998). There is 
also evidence that LCA downregulates NF-kB (a protein complex that has been linked to 
cancer, inflammatory, and autoimmune diseases) in colonic cancer cells (Sun et al., 2008). 
This study identified that LCA as a vitamin D receptor (VDR) ligand acted synonymously 
to the hormonal form of vitamin D which is involved with anti-inflammatory action 
through VDR. Colonic cell lines were used to illustrate these effects and it was shown 
specifically that LCA decreased IL-8 secretion induced by IL-1β. Patients with 
Clostridium difficile infection have increased fecal primary bile acids compared to healthy 
donors before fecal microbial transplant (Weingarden et al., 2014). It has been 
hypothesized that the pro-germination properties belonging to taurocholic acid (a primary 
bile acid) are essential to C. difficile growth.
 20 
 
Table 2. Summary of bile acid alterations in studies on intestinal inflammation. 
Source  Species  Study Population  Experimental Design  Testing Method  Alterations in Bile Acids (Results) 
(Lajczak et al., 2015)  human  T84 colonic epithelial cells 
colonic epithelial cells 
wounded by scratching 
with a pipette tip, 
treated with either DCA 
(150 µM) or 
ursodeoxycholic acid 
(100 µM)  
NA 
In controls, after 48 hours wounds spontaneously closed to 
37% wound size of baseline values. In presence of DCA, 
would healing was reduced (i.e., 76% wound size). In 
presence of UDCA and DCA, UDCA completely prevented 
inhibition of wound closure by DCA. FXR mimicked DCA 
effects on wound healing. 
(Bazin et al., 2015)  human 
Crohn's disease 
n=25 
ulcerative colitis 
n=27 
healthy controls 
n=28 
fecal samples from 
patients with IBD 
liquid 
chromatography 
coupled with 
tandem mass 
spectrometry 
Isomerization of LCA (reported as Iso‐LCA/LCA) was 
decreased compared with controls (10% vs. 20%, 
respectively) and was lower in flare vs. remission (8.5% vs 
14%, respectively). 
(Gothe et al., 2014)  human 
Children with 
Crohn's disease 
(n=44) 
Children with 
ulcerative colitis 
(n=14) 
measurement of bile 
acid malabsorption in 
children with 
inflammatory bowel 
diseases 
7 alpha‐
hydroxy‐4‐
cholesten‐3‐one 
(C4) by HPLC 
C4 concentrations increased in 23% of CD patients but only 
one ulcerative colitis patient. Crohn's disease patients with 
diarrhea had significantly higher C4 values compared to 
those without (76.9 vs. 30.45 ng/mL). 
(Degirolamo et al., 2014)  mouse  C57BL/6J 
Mice were treated with 
VSL#3 probiotics and 
feces were collected to 
measure bile acid 
metabolism and 
receptor signaling 
liquid 
chromatography 
coupled with 
tandem mass 
spectrometry 
Increased BA deconjugation and fecal excretion in VSL#3 
treated mice | increased hepatic synthesis and biliary 
output and repression of FXR/FGF15 which can be reversed 
by FXR agonist. 
(Dossa et al., 2016)  rat  IEC‐6 cells  EGFR an FXR pathway in cell proliferation 
cell culture and 
qPCR 
TCA induces intestinal cell proliferation and in contrast DCA 
inhibits proliferation. 
(Rau et al., 2016)  mouse 
C57‐BL/6J‐Fue 
and BL6‐
IL10tmlCgn (IL10‐
/‐) 
analyzed the 
enterohepatic regulation 
of FGF15‐mediated 
pathways in 2 different 
IBD mouse models 
qPCR, Western 
Blot, Elisa, 
HPLC‐MS/MS 
DSS colitis mice had increased serum FGF15, while IL10‐/‐had 
a trend toward decreased FGF15 serum concentrations. 
Downregulation of FXR mRNA expression in both models. 
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Table 2. Continued. 
Source  Species  Study Population  Experimental Design  Testing Method  Alterations in Bile Acids (Results) 
(Jahnel et al., 2014)  human 
mucosal biopsy 
specimens from 
Crohn's disease 
patients (n=21) 
ulcerative colitis 
patients (n=14) 
healthy controls 
(n=9) 
BA transporters, 
detoxifying systems, and 
nuclear receptors that 
regulate BA transport 
and detoxification were 
targeted and assessed 
qPCR 
Main ileal BA uptake transporter (i.e., apical sodium 
dependent bile acid transporter) was downregulated in 
active CD and UC and CD in remission.  
(Dwyer et al., 2015)  human  T84 colonic epithelial cells 
Investigated the effect of 
the FXR agonist, 
GW4064 on miRNA 
expression in colonic 
epithelial cells 
miRNA profiling 
by Nanostrint 
Tech. and 
Target Scan 
Found to increase expression of epithelial miR‐29a‐3p and 
reduce expression of its target PTEN, deduced possibility of 
FXR agonists to help preserve intestinal barrier function by 
inhibiting apoptosis. 
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Bile acid receptors and inflammation 
The Farnesoid X Receptor (FXR) has been identified as a prominent nuclear 
receptor that controls bile acid and glucose homeostasis (Ma et al., 2006). The pregnane 
X receptor (PXR), also expressed in the intestine and in the liver, can trigger phase I 
detoxification metabolism through induction of Cytochrome P450, subfamily A (CYP3A). 
Lastly, VDR, is activated in the intestine by bile acids and plays a role in inhibition of bile 
acid synthesis by upregulating CYP3A. FXR is activated by any one of the main primary 
and secondary bile acids (i.e., cholic, chenodeoxycholic, lithocholic, and DCA), while 
VDR is primarily activated by LCA and PXR is activated by UDCA and LCA (Pols et al., 
2011).  
 A variety of membrane receptors are also preferentially activated by the bile acid 
pool, namely G-protein coupled receptors (GPCR) (activated by any one of the primary 
and secondary bile acids), muscarinic receptors (activated by lithocholic and DCA), and 
formyl-peptide receptors (FPRs) (activated by DCA and chenodeoxycholic acid (CDCA)) 
(Raufman et al., 2002). FPR receptors can be located in neutrophils and monocytes and 
when activated are believed to induce cell chemotaxis and aid in the identification of 
damaged tissue; moreover, this likely contributes to the anti-inflammatory properties of 
bile acids (Chen et al., 2000).  
 TGR5 is a G protein-coupled receptor specific for bile acids that is present on the 
cell-surface (Kawamata et al., 2003). Kupffer cells have an abundant expression and 
presence of TGR5 among resident macrophages (Keitel et al., 2008). Furthermore, cyclic 
adenosine monophosphate (cAMP) has been reported to inhibit lipopolysaccharide (LPS)-
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induced cytokine secretion, which may be activated by bile acids given their capability to 
activate TGR5 and subsequently trigger increased cAMP production in alveolar 
macrophages. The same study in alveolar macrophages noted that bile acids reduced 
phagocytic activity in these cells and inhibited LPS-induced production of pro-
inflammatory cytokines (i.e., tumor necrosis factor-α (TNF-α), Interleukin (IL)-1α, IL-1β, 
IL-6, and IL-8), (Kawamata et al., 2003). Kuppfer cells isolated from rat show that TGR5 
agonists such as oleanolic acid, tauurolithocholic acid, as well as CAMP can result in 
reduced expression of proinflammatory cytokines (i.e., IL-1α, IL-1β, IL-6 and TNF- α) 
(Keitel et al., 2008).  
Historically, IBD in humans was tentatively linked to bile acid malabsorption in 
some individuals. A recent study in humans that examined serum and fecal samples of 42 
IBD patients and 29 healthy subjects aimed to connect microbial dysbiosis, bile acid 
dysmetabolism, and gut inflammation in patients with IBD (Duboc et al., 2013). Fecal 
conjugated bile acids were significantly increased in active IBD (Standard error of the 
mean (SEM): ~9 and ~3%, in active IBD compared with healthy controls, respectively). 
In contrast, fecal and serum unconjugated secondary bile acid concentrations were 
significantly decreased in IBD (SEM: ~50 and ~20%, respectively) compared with healthy 
controls (SEM: ~90 and ~32%, respectively). The recent abstract by Honneffer et al. 
(2015) described a similar pattern in fecal secondary bile acids in dogs with IBD. This 
may indicate that a so-called bile acid dysmetabolism may be present in humans and dogs, 
and may deserve further investigation in canine medicine. 
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Bile acid sequestrants 
Bile acids sequestrants may be a potential therapeutic option as they have been 
used to help treat hyperlidemia, bile acid malabsorption, and primary sclerosing 
cholangitis among many other diseases (Scaldaferri et al., 2013). Cholestyramine is a bile 
acid sequestrant which is capable of binding bile acids in the gastrointestinal tract to 
prevent reabsorption and accumulation. It is most well-known for its capacity as a strong 
ion exchange resin working through the exchange of chloride anions with anionic bile 
acids which utilizes a resin matrix. Functionally, the exchange resin consists of a 
quaternary ammonium group (positively charged polyatomic ions) attached to an inert 
styrene-divinylbenzene copolymer. Cholestyramine has been marketed under the trade 
names Questran, Questran Light, Cholybar, and Olestyr (Pepper, 1986). 
 Cholestyramine has reportedly been used in several clinical instances regarding 
the treatment of cyanobacterial poisoning in dogs and anecdotally in the treatment of 
hypercholesterolemia as well as chronic diarrhea. In one case report, a two and a half year 
old spayed female Miniature Australian Shepherd presented with acute onset of anorexia, 
vomiting, and depression (Rankin et al., 2013). Feces from the affected dog were positive 
for cyanobacterial biotoxin, microcystin-LA (217ppb). After 8 days of hospitalization and 
supportive fluid therapy, and administration of mucosal protectants, vitamins, antibiotics, 
and supplements, the bile acid sequestrant cholestyramine was administered orally. Rapid 
clinical improvement was noted. In rats, cholestyramine has been show before to bind 
>99% of microcystin-LR in vitro and in vivo (Dahlem et al., 1989).  
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Another study used cholestyramine in dogs to investigate the effect on bile acids 
in feces and in serum  (Jansen and Zanetti, 1965). This study only reported the sum of 
DCA, CDCA, and CA without identifying the concentrations of each individual bile acid. 
Nevertheless, the study identified the cholesterol lowering property of cholestyramine as 
part of the serological tests it reported. Cholestyramine increased bile acid concentrations 
in feces in a dose dependent fashion from 1 gram per day to 6 grams per day. While 
malabsorption of bile acids in people is relatively well described now, little has been 
described before in dogs. One study in 17 dogs with chronic diarrhea measured serum 
concentration of 7α-hydroxy-4-cholesten-3-one (C4) in dogs as a potential target for bile 
acid malabsorption (Kent et al., 2016). Results from this study indicated that 3 of the 17 
dogs had a C4 concentration above the range for clinically healthy dogs and were also 
poorly responsive to conventional therapy. Serum C4 concentrations are indicative of 
major enzymes in the bile acid synthesis pathway and studies in humans show good 
correlation with the rate of bile acid synthesis (Gälman et al., 2003).  
 Idiopathic bile acid diarrhea was first described in 1975 and is now recognized a 
common cause of chronic diarrhea in human patients (Williams et al., 1991). The 
pathophysiology of the disease is somewhat unclear, however, it is thought to in part 
involve defective reabsorption of bile acids either in the ileum or in the colon. 
Mechanistically, diarrhea is thought to be caused by secretion of sodium and water into 
the colon due to increased colonic permeability (Mekhjian et al., 1971; AMIN, 1981). 
Alternatively, it has been hypothesized that diarrhea could be caused by accelerated 
colonic transit, increased secretion of mucus, and stimulation of defecation (Sadik et al., 
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2004). Cholestyramine has been effectively shown to help treat patients with idiopathic 
bile acid diarrhea to help ameliorate aforementioned symptoms of the disease. For 
instance, in an open-label study using cholestyramine in patients with bile acid diarrhea, 
cholestyramine was shown to significantly prolong transit in the transverse part of the 
colon. There was also a trend for prolonged transit in the small bowel. 
 The gold standard test for bile acid malabsorption has traditionally been the 
SeHCAT (23-seleno-25-homotaurocholic acid) test. The procedure uses a capsule 
containing radiolabeled SeHCAT, which is taken orally and monitors recirculation of bile 
acids. Patients are scanned periodically by a gamma camera in the supine position and 
values above 15% are considered to be normal while values less than 15% are considered 
to be indicative of excess bile acid loss. Testing with SeHCAT is limited because only bile 
acid fluctuations in the small intestine are measured (Bajor et al., 2009).  
Cholestyramine is suggested as a therapeutic agent is in the treatment of diarrhea-
predominant irritable bowel syndrome (IBS-D) (Camilleri, 1999). However, IBS-D is 
primarily associated with small bowel and proximal colonic transit and, therefore, 
loperamide is generally prescribed to decrease intestinal transit, enhancing intestinal water 
and ion absorption (VASSALLO et al., 1992). It is estimated that about one-third of 
patients with IBS-D have evidence of increased bile acid synthesis or excretion. Bile acid 
sequestrants are commonly used and efficacious in improving stool consistency in many 
of these cases (Camilleri et al., 2015). There is mounting evidence that supports the 
intervention of bile acid metabolism in patients with GI disease, however, further studies 
will need to fully characterize the physiological effects as well as therapeutic targets 
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necessary to alter the disease state. 
Hypothesis and objectives 
The hypotheses of this research were that the fecal metabolome undergoes 
continuous alterations after therapy in dogs with chronic GI disease, also that bile acids 
may play a role in the disease process and that there may be value in manipulating bile 
acid pool in some canine patients. 
The objectives of this study were to:  
(1) develop a GC/MS assay for the quantification and identification of 
fecal bile acids in dogs, 
(2) measure fecal bile acids in dogs with CE in addition to monitoring 
their long term outcome, 
(3) characterize the fecal metabolome in dogs with IBD over time, 
(4) and lastly, describe the effect of cholestyramine (a bile acid 
sequestrant) on the fecal bile acid pool and microbiome in healthy 
dogs as a preliminary understanding in its potential usefulness as an 
alternate or adjunct therapy to dogs with chronic GI disease. 
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CHAPTER	II  
DEVELOPMENT OF A GAS CHROMATOGRAPHY/MASS 
SPECTROMETRY ASSAY FOR THE MEASUREMENT OF FECAL 
UNCONJUGATED BILE ACIDS IN DOGS	
Overview	
 Bile acids play an important role in dietary regulation. In the gastrointestinal tract, 
the primary bile acids are CA and CDCA (i.e., the primary bile acids), while LCA, DCA, 
and UDCA are the major secondary bile acids. The small intestine has a large proportion 
of primary bile acids that are conjugated to taurine or glycine, while the large intestine 
harbors a large proportion of secondary bile acids that have been deconjugated and 
dehydroxylated by colonic bacteria. There is mounting evidence in humans that bile acids 
play a role in maintaining gastrointestinal health and bile acid dysmetabolism may play a 
role in GI disease. Bile acid dysmetabolism may also be present in dogs with 
gastrointestinal disease. Therefore, an in-house assay was developed using gas-
chromatography coupled with mass spectrometry to rapidly assess fecal bile acid profiles 
in dogs. The lower limit of quantification (LLOQ) and upper limit of quantification 
(ULOQ) were as follows for each compound: CA (3.9 and 1000 µg/mL), CDCA (6.25 and 
200 µg/mL), LCA (1.9 and 500 µg/mL), DCA (31.3 and 1000 µg/mL), and UDCA (0.78 
and 50 µg/mL). For intra-assay variability, the average coefficient of variation (CV%s) 
were: 6.0, 5.6, 7.1, 7.3, and 8.8% for CA, CDCA, LCA, DCA, and UDCA, respectively. 
For inter-assay variability, the average CV%s were: 8.3, 8.0, 4.8, 8.6, and 13.2% for CA, 
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CDCA, LCA, DCA, and UDCA, respectively. The assay was found to be both precise and 
reproducible for the identification and quantification of unconjugated fecal bile acids in 
dogs. 
Introduction	
 Bile acids are a product of cholesterol and are essential to the process of excreting 
bile lipids while also aiding in the absorption of dietary lipids and fat soluble vitamins (de 
Aguiar Vallim et al., 2013). Bile is mainly comprised of three classes of biliary lipids: bile 
acids, phospholipids, and cholesterol. Bile acids are responsible for the formation of mixed 
and simple micelles. Micelles act preventatively in the gall bladder to inhibit cholesterol 
crystallization as well as gall stone formation (Di Ciaula et al., 2013). While bile acids can 
be protective against some of the consequential effects of cholesterol, bile itself delivers 
somewhere between 500-2400 mg of cholesterol per day to the intestine which is nearly 
five times the dietary intake of western-diets consumed by humans (Mok et al., 1979). 
 Once bile acids are secreted into the duodenum, they are reabsorbed and returned 
to the liver via portal venous circulation. During recirculation they are prepared once again 
to be re-secreted in to the intestine. It is generally agreed that less than 5-10% of bile acids 
escape reabsorption and are later eliminated into the feces (Dawson et al., 2003). This is 
considered a highly efficient process of enterohepatic circulation and bile acids undergo 
several distinct types of absorption along the gastrointestinal tract. This reabsorption 
means that approximately less than 10% of bile acids are a product of de novo hepatic 
synthesis. Firstly, both unconjugated and conjugated bile acids undergo passive absorption 
via electrochemical gradients in the jejunum, then, active transport in the distal (i.e., 
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terminal) ileum via the apical sodium bile acid cotransporter (ASBT, gene name: Slc10a2), 
and finally passive absorption in the colon (Schiff et al., 1972). Bile acids undergo a 
complex process of reabsorption whereby the co transporter (mechanistically, sodium and 
membrane potential driven) moves both unconjugated and conjugated bile acids from the 
lumen across the apical brush border membrane. Once this has been facilitated, bile acids 
are then moved to the basolateral membrane before being secreted into portal circulation 
where they can once again be transported across the sinusoidal membrane of the 
hepatocyte and lastly be re-secreted, and re-conjugated to then move across the canalicular 
membrane into bile (Dawson, 2011). 
 Bile acids have been suspected to be carcinogens in the gastrointestinal tract and 
are thought to act through the degradation of DNA  (Bernstein et al., 2005). Increased bile 
acids have been implicated in the pathogenesis of irritable bowel syndrome (IBS) and may 
contribute to intraluminal and mucosal factors that may induce critical and detrimental 
changes in the gut (Camilleri, 2012). Previous reports have suggested that in as many as 
32% of patients with IBS-diarrhea type symptoms a bile acid malabsorption (BAM) is 
present and in-fact when treated with bile acid sequestrants seem to improve (Wedlake et 
al., 2009).  
 In dogs, similar disease pathologies exist for patients with chronic diarrhea. 
Idiopathic inflammatory bowel disease (IBD), for instance, is a gastrointestinal tract 
disorder of unknown cause and ill-defined pathogenesis (Jergens et al., 2003). The clinical 
signs are highly variable but can include vomiting, diarrhea, and weight loss.  A diagnosis 
of canine IBD is typified by confirmed intestinal inflammation and empirical treatment 
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(e.g., antibiotics, food, and steroids). To elucidate the role of bile acids in canine 
gastrointestinal disease, the goal of this study was to develop and validate an in-house gas 
chromatographic/mass spectrometry assay that could readily evaluate fecal unconjugated 
bile acids in dogs.  
	Materials and methods	
  For the identification and quantification of unconjugated bile acids, the protocol 
was adapted and modified from methods previously described (Batta et al., 1999; Batta et 
al., 2002). Unconjugated CA, CDCA, LCA, DCA, and UDCA were all purchased in 
powder form from a commercial supplier (Sigma-Aldrich, St. Louis, MO). Internal 
standards CA-d4 and LCA-d4 were purchased from CDN Isotopes (Quebec, Canada).  All 
compounds were >95% pure as judged by thin-layer chromatography. Hydrochloric acid 
(37% American Chemical Society reagent), hexane (for high-performance liquid-
chromatography (HPLC)), 1-butanol for HPLC, and derivitization agent (Supelco’s® 
Sylon HTP HMDS + TCMS + Pyridine, 3:1:9 Kit) was used for preparation of 
trimethylsilylation (TMS) ether bile acid derivatives. 
 Naturally voided fecal samples were collected from healthy dogs and dogs with 
gastrointestinal disease. Approximately 0.5 g of wet feces was aliquoted into a tube (5 mL, 
57x15.3 mm, polypropylene, Sarstedt, Nümbrecht, Germany) using a spatula (Smart 
Spatula. USA Scientific, Ocala, FL). Fecal samples were kept frozen at -80˚ C and then 
lyophilized overnight (Labconco FreeZone 2.5 Plus, Kansas City, MO). Samples were 
then removed from the lyophilizer and pulverized and aliquoted using a spatula (Smart 
Spatula. USA Scientific, Ocala, FL) into a disposable glass centrifuge tube (5 mL, Kimble-
 32 
 
Chase, Rockwood, TN). Approximately 10-15 mg of lyophilized feces were used for 
downstream extraction. The amount of bile acid was later back calculated according to the 
original weight of the aliquot to normalize for varying starting fecal weights. A total 
volume of 200 µL of butanol containing the internal standards CA-d4 and LCA-d4 was 
added to each fecal sample. Twenty microliters of HCl was then added for a final volume 
of 220 µL and vortexed for 30 seconds. Samples were then capped and incubated at 65˚ C 
for 4 hours. Next, samples were evaporated under nitrogen gas until dryness at 65˚ C for 
approximately 25 minutes. Two-hundred microliters of derivitization agent were then 
added to the sample and incubated at 65˚ C for 30 minutes. Following incubation, samples 
were again evaporated under nitrogen gas until dryness at 65˚ C (approximately 25 
minutes). Samples were then re-suspended in 200 µL of hexane, vortexed briefly then 
centrifuged for 10 minutes at 3200 rcf. A 100 µL aliquot was then transferred to a GC/MS 
vial insert (250 µL glass with polymer feet, Agilent, Santa Clara, CA) and the vial was 
capped for further downstream analysis. 
 Gas chromatography (GC) and mass spectrometry (MS) was used (6890N and 
5975 inert Mass Selective Detector, Agilent, Santa Clara, CA). The instrument was 
equipped with an auto sampler (7683 Series, Agilent, Santa Clara, CA).  A capillary 
column (DB-1ms Ultra Inert, Agilent, Santa Clara, CA) was used with the following 
dimensions: length: 30 m, diameter: 0.250 mm, film: 0.25 µm. A 20:1 split ratio was 
utilized after a 1 µL sample injection with an inlet temperature of 250˚ C. After injection, 
oven temperature was kept at 150˚ C for 1 minute, then ramped at 21˚ C per minute to a 
final temperature of 276˚ C then held at that temperature for 21 minutes. At 28 minutes 
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the oven was ramped to 325˚ C for 3 minutes for post run column cleaning. Helium was 
used as the carrier gas at an approximate flow rate of 1 mL/min varying slightly with 
pressure to account for retention time locking to the compound cholestane-d4 set to elute 
at 11.4 minutes. Mass spectral data was analyzed using ChemStation (Agilent’s Enhanced 
Data Analysis in MSD version D.02.002.275). 
 The panel for fecal unconjugated bile acids was analytically validated by 
determination of accuracy and reproducibility by evaluating intra- and inter-assay 
variability, respectively. Calibration curve recovery was calculated as observed value 
(µg/mL)/expected value (µg/mL) x 100%. Accuracy was evaluated by assaying 6 aliquots 
taken from a single fecal sample from 4 dogs on the same run/day followed by calculating 
the intra-assay coefficients of variation (CV = [SD/mean] x 100%). Reproducibility of the 
assay was determined by assaying 6 aliquots taken from a single fecal sample from 4 dogs 
on 6 consecutive days followed by calculating inter-assay CV. Upper limit of 
quantification and LLOQ were established by standard curve development that spanned 
the working range of the assay useful in detecting a variety of fecal bile acid concentrations 
from a variety of dogs that belonged to students at Texas A&M University. 
Results	
 Each individual bile acid underwent individual extraction as per the materials and 
methods section. Retention time was logged and used to further develop an acquisition 
protocol using ChemStation by Agilent. Target ions were selected via ion chromatograms 
for each individual bile acid being CA, CDCA, LCA, DCA, and UDCA as follows: 253.3, 
412.4, 215.3, 255.3, and 502.5, respectively. Qualifier ions along with their relative 
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percent response were also selected to ensure proper compound identification and were as 
follows for CA, CDCA, LCA, DCA, and UDCA: 410.4, 255.3, 257.3, 256.3, and 503.5, 
respectively. Their relative response ratios for qualifier ions belonging to CA, CDCA, 
LCA, DCA, and UDCA were: 66.3%, 45.7%, 88.1%, 21.4%, and 46.5%, respectively.  
 Deuterated internal standards were used to confirm identity of primary and 
secondary bile acids while also serving as a control for extraction efficiency during the 
extraction and butyl esterification process of fecal bile acids. D4-CA was used as a 
surrogate internal standard marker for all primary bile acids (i.e., CA and CDCA), while 
D4-LCA was used as a surrogate internal standard marker for all secondary bile acids (i.e., 
LCA, DCA, and UDCA). The target ion, qualifier ion, and relative response ratio for D4-
CA was 257.3, 414.5, and 77.7%, respectively. The target ion, qualifier ion, and relative 
response ratio for D4-LCA was 219.3, 261.3, and 85.8%, respectively. These results are 
available in Table 3. 
Intra-assay validation and precision testing for fecal samples F1-F4 yielded an 
average CV of 7% for all compounds and all samples analyzed. More specifically, for 
intra-assay variability, the average CV%s were: 6.0, 5.6, 7.1, 7.3, and 8.8% for CA, 
CDCA, LCA, DCA, and UDCA, respectively. Inter-assay validation and reproducibility 
testing for samples F5-F8 yielded an average CV of 8.62% for all compounds and all 
samples analyzed. More specifically, for inter-assay variability, the average CV%s were: 
8.3, 8.0, 4.8, 8.6, and 13.2% for CA, CDCA, LCA, DCA, and UDCA, respectively. These 
results are summarized in Table 4. The LLOQ and ULOQ for 
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Table 3. Ions profile for GC/MS Single Ion Monitoring 
   RT (min)  Target Ion Qualifier Ion  Relative Response %
D4‐CA‐n‐butyl ester  25.56  257.30  414.50  77.70 
CA‐n‐butyl ester  25.71  253.30  410.40  66.30 
CDCA‐n‐butyl ester  25.38  412.40  255.30  45.70 
D4‐LCA‐n‐butyl ester  22.49  219.30  261.30  85.80 
LCA‐n‐butyl ester  22.48  215.30  257.30  88.10 
DCA‐n‐butyl ester  24.56  255.30  256.30  21.40 
UDCA‐n‐butyl ester  26.82  502.50  503.50  46.50 
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Table 4. Precision and reproducibility of the GC/MS assay for unconjugated bile acids. 
Fecal Sample  mean (µg/mg) ± standard deviation (µg/mg)  coefficiant of variation (%) 
Intra‐Assay Variability  CA  CDCA  LCA  DCA  UDCA  CA  CDCA  LCA  DCA  UDCA 
F1  3.01±0.464  0.90±0.093  0.61±0.084  5.69±0.699  0.03±0.004  15.43  10.32 13.71 12.30  16.01 
F2  0.34±0.005  0.24±0.010  0.13±0.005  0.41±0.021  0.26±0.014  1.60  4.21  3.64  5.17  5.44 
F3  2.63±0.105  0.45±0.017  0.20±0.016  4.57±0.284  0.07±0.003  3.99  3.83  8.02  6.20  4.92 
F4  0.45±0.014  0.23±0.009  0.63±0.020  4.40±0.254  0.18±0.016  3.19  4.08  3.12  5.78  9.01 
Inter‐Assay Variability   
F5  0.22±0.012  0.23±0.024  1.28±0.040  3.51±0.440  0.05±0.007  5.36  10.42 3.13  12.55  15.14 
F6  3.10±0.214  1.75±0.085  2.62±0.188  13.36±0.800 0.22±0.024  6.90  4.83  7.18  5.99  10.58 
F7  0.21±0.020  0.26±0.012  0.51±0.021  2.42±0.204  0.02±0.003  11.22  12.05 5.13  7.44  12.23 
F8  0.19±0.021  0.20±0.024  1.58±0.081  7.89±0.587  0.02±0.002  9.77  4.87  4.12  8.42  14.96 
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each compound were: CA (3.9 and 1000 µg/mL), CDCA (6.25 and 200 µg/mL), LCA (1.9 
and 500 µg/mL), DCA (31.3 and 1000 µg/mL), and UDCA (0.78 and 50 µg/mL). OE 
ratios for all compounds were between 77% and 123%. 
Discussion	
 Gas chromatography coupled with mass spectrometry or variants of compound 
detection such as flame ionization are commonly used methods for the identification and 
quantification of fecal bile acids in stool and serum (Batta et al., 1999). High-performance 
liquid chromatography (HPLC) coupled with mass spectrometry is also used (Kakiyama 
et al., 2014). The objective of this study was to develop and analytically validate an assay 
for the measurement and identification of unconjugated fecal bile acids in canine feces. 
Results from this study indicate that the adapted method from Batta et al. was sufficient 
in extracting and measuring fecal bile acids in dogs. The technique itself is was found to 
be highly efficient since there was no step requiring prior isolation and separation of bile 
acids from feces, a process that can significantly slow sample data acquisition times. 
 Several parameters were examined to confirm the precision and reproducibility of 
the assay. This assay does not use a fecal extraction process producing a liquid extract that 
can then be normalized by volume for sample injection. Instead, feces undergo direct 
isolation and derivatization prior to being reconstituted in a hexane solution to be 
analyzed. For the intra-assay variability a CV < 16.5% was achieved among all 
compounds (i.e., CA, CDCA, LCA, DCA, and UDCA) for the four fecal samples 
measured. For the inter-assay variability a CV < 15.5% was achieved among all 
compounds (i.e., CA, CDCA, LCA, DCA, and UDCA). While this is slightly above 
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standards in the field (Bansal and DeStefano, 2007) that support an acceptable CV of < 
15%, this is likely due to heterogeneity in a fecal compound matrix and not a fluctuation 
in the machine. Furthermore, observed to expected ratios for calibration curves were found 
to be acceptable for bile acids measured. 
 A complete and thorough stability study is needed to fully assess the integrity of 
fecal bile acids during storage. Samples that contained fecal bile acids at amounts well 
within the calibration curve for each respective bile acid CA, CDCA, LCA, DCA, and 
UDCA were used for this pilot study. In some instances, only one compound was used for 
stability assessment since the others did not fall well within the calibration curve for the 
other compounds. However, pilot data suggests that once feces are lyophilized and stored 
at -80° C, the results are reproducible over two months later. Table 5 shows that a CV of 
< 11% was found for each compound. This suggests that fecal samples, once stored, are 
stable at -80° C conditions. Further studies are needed to assess the stability of compounds 
under room temperature and refrigerator conditions. Additionally, this study did not 
evaluate to see whether or not there was an effect of freezing and thawing samples before 
bile acid extraction. Inherently, due to protocol limitations, all samples must be frozen at 
least once to undergo lyophilization, which makes it difficult to run truly fresh fecal 
samples. Some anecdotal evidence and studies suggest that feces be frozen immediately 
as bile acids do not remain stable at room temperature (Camilleri et al., 2009). 
  Drawbacks of this assay are that it cannot be used for analysis of conjugated fecal 
bile acids (Batta et al., 1999). This could be especially limiting when needing to assess 
pathological and bile acid functional conditions in germ-free mice (Sayin et al., 2013a). 
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Table 5. Stability of fecal bile acids after 2 months storage at ‐80° C. 
Fecal Sample  Time point Compound  ug/mg  CV% 
F1  Baseline  cholic acid  2.9353 1.18 
F1  2 months  cholic acid  2.8666
F2  Baseline  chenodeoxycholic acid  1.6640 9.37 
F2  2 months  chenodeoxycholic acid  1.3788
F3  Baseline  lithocholic acid  1.4160 6.87 
F3  2 months  lithocholic acid  1.2338
F4  Baseline  deoxycholic acid  9.3218 10.53 
F4  2 months  deoxycholic acid  7.5456
F5  Baseline  ursodeoxycholic acid  0.0151 1.17 
F5  2 months  ursodeoxycholic acid  0.0147   
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CHAPTER III  
MEASUREMENT OF FECAL BILE ACIDS IN DOGS WITH CHRONIC 
ENTEROPATHY 
Overview	
 Chronic enteropathy in dogs is poorly defined and diagnostic tools are limited. It 
is often a diagnosis of exclusion. Nevertheless, genetic predisposition, nutritional 
influence, and intestinal microbiota and their metabolites are likely to be involved. 
Mounting evidence in humans suggests that bile acid dysmetabolism may play a role in a 
variety of chronic GI diseases (i.e., Crohn’s disease, bile acid malabsorption, IBS-D, IBD, 
and Ulcerative Colitis). In fact, it is thought that approximately one third of patients with 
IBS-D have a bile acid dysmetabolism. These are generally diagnosed by either bile acid 
malabsorption tests (i.e., SeHCAT or C4) and typified by a presence of increased primary 
bile acids in large intestine. Therefore, the purpose of this study was to characterize the 
fecal unconjugated bile acid profile in dogs with CE.  
 Cholic acid was significantly increased in dogs with CE compared to healthy dogs 
(p=0.0425). LCA and DCA were significantly decreased in dogs with CE (p=0.0006 and 
0.0098, respectively). A reference interval (i.e., 54-96%) was established for the percent 
of secondary bile acids in the feces of healthy dogs. Twenty out of 34 patients with CE 
had a fecal bile acid profile outside of the healthy reference interval. Further studies are 
needed to understand how this may effect therapeutic strategies in treating CE in dogs. 
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Introduction	
Canine CE in dogs is characterized by a poorly defined pathogenesis and highly 
variable clinical signs  (Jergens et al., 2003). Typical presentation of CE in dogs may 
include watery diarrhea, vomiting, and anorexia (Schreiner et al., 2008). While 
pathogenesis of CE in dogs is not well understood, it is generally thought to involve 
microbial dysbiosis, functional alterations of microbiota (dysmetabolism), an underlying 
host genetic susceptibility, and environmental factors (Simpson and Jergens, 2011; 
Minamoto et al., 2014b). Ultimately, the interworking between intestinal homeostasis 
(e.g., impact of dysbiosis and dysmetabolism) and clinical signs in patients with CE still 
lacks understanding. 
 Mounting evidence suggests that the microbiota and their metabolites play a 
regulatory role throughout the intestine (Suchodolski et al., 2012a; Suchodolski et al., 
2012b). Furthermore, the microbiota is responsible for multiple metabolic functions, one 
of which includes metabolism and regulation of bile acids (Sayin et al., 2013b). Bile acid 
production first occurs in the liver from cholesterol where the primarily bile acids CA and 
chenodeoxycholic are synthesized. Primary bile acids are then conjugated with either 
taurine or glycine in the liver and stored in the gall bladder (Ridlon et al., 2016). Upon 
release of bile acids into the small intestine following a meal, their role includes nutrient 
digestion and solubilizing vitamins (Dawson and Karpen, 2015). While the majority of 
enterohepatic absorption and recirculation of bile acids occurs at the terminal ileum, 
approximately 5% are excreted into the colon and deconjugated and dehydroxylated by 
colonic bacteria forming the secondary bile acids DCA, LCA, and UDCA (Hill and 
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Drasar, 1968; Ridlon et al., 2016). Thus, microbial dysbiosis identified in patients with 
CE may negatively affect gut homeostasis through bile acid dysmetabolism.  
 Studies in humans have suggested a role for bile acid dysmetabolism in gut 
inflammation and in inflammatory bowel diseases (Kruis et al., 1986; Duboc et al., 2013). 
Patients with IBD have a decreased percentage of secondary bile acids in feces. Duboc et 
al. (2013) also described a concurrent dysbiosis in patients with IBD and have shown in 
vitro experiments, which reflect decreased IL-8 response in the presence of DCA and 
LCA. A collection of work in humans with diarrhea predominant irritable bowel syndrome 
(IBS-D) has identified an increase in primary bile acids which affects approximately one 
third of patients and symptoms can often times be managed by bile acid sequestrants (e.g., 
cholestyramine) (Wedlake et al., 2009; Duboc et al., 2012; Shin et al., 2013). Despite a 
growing body of information describing fecal bile acids in humans with chronic GI 
disease, studies investigating the role of bile acids in the feces of dogs is limited.  
 Increased serum C4 has been reported in a subset of dogs with chronic diarrhea 
(Kent et al., 2016). Untargeted metabolomics conducted in feces of canine patients with 
inflammatory bowel disease have also described bile acid dysmetabolism (Honneffer et 
al., 2015b). Therefore, the objective of this study was measure fecal bile acids in healthy 
dogs and dogs with CE. 
Materials and methods	
 Fecal samples from healthy dogs (n=24) were collected from pets belonging to 
personnel at Texas A&M University’s College of Veterinary Medicine and immediately 
stored at -80° C until further analysis. Dogs with CE (n=34) were prospectively enrolled 
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from multiple centers including the Evidensia Specialist Animal Hospital in Helsingborg, 
Sweden, Iowa State University (ISU), Colorado State University (CSU) , San Diego 
Specialty Hospital (SDSH), and private clinics around the United States which submitted 
fecal samples to the Inflammatory Bowel Disease study at Texas A&M University 
(http://vetmed.tamu.edu/gilab/research/canine-ibd). Similarly, fecal samples were 
collected and immediately stored at -80° C until further analysis.  Patients that were 
enrolled into the CE group had gastrointestinal clinical signs lasting three weeks or more 
in duration. A subset of those patients were followed-up over the period of three and 8 
weeks after initial diagnosis and then over a year later. For the majority of patients, 
standard therapy involved sequential implementation of a food trial, antimicrobial 
intervention, followed by an immunosuppressive drug if they failed to respond to either. 
Dietary intervention generally consisted of a hydrolyzed diet or a diet consisting of a novel 
protein source as is typical with a workup for dogs with chronic signs of gastrointestinal 
disease.  
 Unconjugated fecal bile acids were measured using a gas chromatographer coupled 
with a mass spectrometer targeting CA, CDCA, LCA, DCA, and UDCA as described 
previously. Bile acid data was described in µg/mg of lyophilized fecal content in addition 
to being expressed as a percent of total fUBA measured. Furthermore, the unconjugated 
primary bile acids CA and CDCA were combined to represent total primary fecal 
unconjugated bile acids (fUBA) measured and LCA, DCA, and UDCA were combined to 
represent total secondary fUBA. Data was tested for normality using a Shaprio Wilk’s test 
and followed by a Mann Whitney test or Friedman’s test where appropriate followed by 
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Dunn’s post testing to identify significant differences between groups. A reference interval 
for healthy dogs was constructed by first removing outliers by means of identifying those 
values that were 1.5 times the length of the box away from either the lower or the upper 
quartiles. The 97.5% percentile was then calculated to represent serve as a standard set of 
values for healthy dogs. A p-value of less than 0.05 was considered significant.  
Results	
 The following represent the changes in fecal bile acids when measuring 
concentration alone. The primary bile acid CA was significantly increased in patients with 
CE (med [min-max]: 1.301 µg/mg [0.018-47.340 µg/mg]) compared with healthy dogs 
(med [min-max]: 0.234 µg/mg [0.068-12.040 µg/mg]; p=0.0425). There was no 
significant difference in concentration of the primary bile acid CDCA between patients 
with CE (med [min-max]: 0.320 µg/mg [0.000-2.959 µg/mg]) compared to healthy dogs 
(med [min-max]: 0.157 µg/mg [0.080-1.301 µg/mg]; p=0.1874). The secondary bile acid, 
LCA, was significantly decreased in patients with CE (med [min-max]: 0.033 µg/mg 
[0.000-5.318 µg/mg]) compared with healthy dogs (med [min-max]: 0.8182 µg/mg 
[0.000-2.388 µg/mg]; p=0.0006). The secondary bile acid, DCA, was significantly 
decreased in patients with CE (med [min-max]: 0.300 µg/mg [0.177-12.020 µg/mg]) 
compared with healthy dogs (med [min-max]: 1.931 µg/mg [0.202-9.101 µg/mg]; 
p=0.0098). There was no significant difference in concentration of the secondary bile acid, 
UDCA, between patients with CE (med [min-max]: 0.010 µg/mg [0.000-3.777 µg/mg]) 
compared with healthy dogs (med [min-max]: 0.022 µg/mg [0.002-0.330 µg/mg]; 
p=0.3556). There was a trend in the total amount of primary bile acids between patients 
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with CE (med [min-max]: 1.873 µg/mg [0.018-50.010 µg/mg]) compared with healthy 
dogs (med [min-max]: 0.415 µg/mg [0.147-13.340 µg/mg]; p=0.0614), however this 
comparison did not reach statistical significance. The total amount of secondary bile acids, 
however, were significantly decreased in patients with CE (med [min-max]: 0.571 µg/mg 
[0.177-15.670 µg/mg]) compared with healthy dogs (med [min-max]: 3.290 µg/mg 
[0.213-11.570 µg/mg]; p=0.0118). There was no significant difference in total fUBA 
between patients with CE (med [min-max]: 4.458 µg/mg [0.336-50.280 µg/mg]) 
compared to healthy dogs (med [min-max]: 3.964 µg/mg [1.507-13.930 µg/mg]; 
p=0.3724). These results are shown in Figure 1. 
The following represent the changes in fecal bile acids as a percent of total fUBA 
measured. The fecal bile acid profile in healthy dogs for CA, CDCA, LCA, DCA, and 
UDCA was (median % values expressed): 5.54%, 5.08%, 21.21%, 61.54%, and 0.51%, 
respectively. The fecal bile acid profile in patients with CE for CA, CDCA, LCA, DCA, 
and UDCA was (median % values expressed) 49.49%, 10.55%, 0.30%, 14.96%, and 
0.23%, respectively. The percent of secondary fUBA were significantly decreased in 
canine patients with CE (median [min-max]: 25.21% [0.53-99.62%]) compared with 
healthy dogs (median [min-max]: 87.98% [4.24-96.50%]; p=0.0161). These results are 
shown in Figure 2. 
In a subset of canine patients with CE (n=16), fecal samples were collected over 
several time points (i.e., baseline or first enrollment, 1 month later, then 2-3 months later). 
The same parameters were measured as described earlier for the entire group where just a 
baseline fecal samples in diseased canine patients were compared to healthy dogs. 
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Lithocholic acid significantly increased in canine patients with CE from baseline (median 
[min-max]: 0.075 µg/mg [0.000-1.071 µg/mg]) to 1 month (median [min-max]: 0.802 
µg/mg [0.000-1.615 µg/mg]) to 2-3 months (median [min-max]: 1.169 µg/mg [0.000-
2.839 µg/mg]) post therapeutic intervention (p-value for Friedman’s test and Dunn’s post-
test (baseline vs 1 month and baseline vs 2-3 months): 0.0005 and <0.05, respectively). 
Deoxycholic acid significantly increased in canine patients with CE from baseline (median 
[min-max]: 0.375 µg/mg [0.204-3.707 µg/mg]) to 1 month (median [min-max]: 3.587 
µg/mg [0.183-11.25 µg/mg])  to 2-3 months (median [min-max]: 5.352 µg/mg [0.192-
16.590 µg/mg]) post therapeutic intervention (p-value for Friedman’s test and Dunn’s 
post-test (baseline vs 1 month and baseline vs 2-3 months)): 0.0004 and <0.05, 
respectively. As such, secondary fUBA significantly increased overall from baseline 
(median [min-max]: 0.5707 µg/mg [0.215-6.680 µg/mg]) compared with 2-3 months 
(median [min-max]: 0.571 µg/mg [0.227-18.080 µg/mg]) post therapeutic intervention (p-
value for Friedman’s test and Dunn’s post-test (baseline vs 2-3 months): 0.0034 and <0.05, 
respectively). Total fUBA increased from baseline (median [min-max]: 3.401 µg/mg 
[0.336-50.280 µg/mg]) compared with 2-3 months (median [min-max]: 8.780 µg/mg 
[2.386-35.680 µg/mg]) post therapeutic intervention (p-value for Friedman’s test and 
Dunn’s post-test (baseline vs 2-3 months): 0.0010 and <0.05, respectively). These results 
are shown in Figure 3.  
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Figure 1. Fecal bile acids in µg/mg and corresponding parameters as measured by 
GC/MS in healthy dogs and dogs with CE. 
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Figure 2. Percent of fecal bile acids and secondary bile acids as a percent of total in 
healthy dogs and dogs with CE. 
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 The percent of secondary fUBA measured were significantly increased overall 
from baseline (median [min-max]: 28.65% [0.53-99.62%]) compared with 2-3 months 
(median [min-max]: 94.53% [1.12-99.27%]) post therapeutic intervention (p-value for 
Friedman’s test and Dunn’s post-test (baseline vs 2-3 months): 0.0183 and <0.05, 
respectively). Chenodeoxycholic acid expressed as a percent of total fUBA measured 
significantly decreased overall from baseline (median [min-max]: 9.23% [0.00-58.59%]) 
compared with 2-3 months (median [min-max]: 2.93% [0.45-15.39%]) post therapeutic 
intervention (p-value for Friedman’s test and Dunn’s post-test (baseline vs 2-3 months): 
0.0152 and <0.05, respectively). There were no other significant changes in the percent of 
total fUBA measured over time. These results are shown in Figure 4. 
Discussion	
 In this study, fecal samples from 24 healthy dogs and 34 dogs with CE were 
evaluated to describe their bile acid profile. In terms of total concentration, the secondary 
bile acids LCA and DCA were both significantly decreased in the CE group. The primary 
bile acid CA was significantly increased in dogs with CE. Anecdotal evidence suggests 
that fecal bile acid profiles are highly variable and therefore, it is also useful to express 
and analyze these data in percent of total bile acids measured or by a simple ratio of 
primary to secondary bile acids (Kamano et al., 1999; Duboc et al., 2013). When utilizing 
this strategy, the same significant findings were noted for CA, CDCA, and LCA. Dogs 
with CE had significantly decreased secondary fUBA when expressed as a percent of total 
fUBA compared to healthy dogs.  
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Figure 3. Fecal bile acids in µg/mg and corresponding parameters as measured by 
GC/MS in dogs with CE from baseline to 2-3 months post therapy. 
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 Figure 4. Bile acids as percent of total fUBA in dogs with CE from baseline to 2-3 
months post therapy. 
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To capture global changes in fecal bile acid profiles a reference interval was 
calculated for the percent of secondary fUBA (Figure 5). A proposed reference interval 
for healthy dogs was constructed by first removing outliers by means of identifying those 
values that were 1.5 times the length of the box away from either the lower or the upper 
quartiles. The 97.5% percentile was then calculated to represent serve as a standard set of 
values for healthy dogs. The upper and lower limits of the reference interval for healthy 
dogs pertaining to the percent of secondary fUBA were 53.57% and 96.47%, respectively. 
 
 
Figure 5. Reference interval for the percent of secondary fUBA in healthy dogs. 
 
 
  
A subset of dogs with CE were followed up over the period of eight weeks. These 
dogs were treated with immunosuppressive therapy after baseline fecal samples were 
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collected. Concentrations of LCA and DCA significantly increased over time. When 
measured as a percent of total fUBA, DCA significantly increased over time, while CDCA 
decreased over time. The percent of secondary fUBA significantly increased over time 
and began to more closely resemble healthy dog profiles. The majority of these patients 
with CE were within the reference interval proposed for healthy dogs by the end of eight 
weeks.  
Fecal bile acid dysmetabolism in canine patients with CE is somewhat of a 
renewed and understudied area in internal medicine. Anecdotal reports of clinicians using 
cholestyramine in the past to treat chronic diarrhea are available, but there is little literature 
to support the evidentiary need or usefulness. In humans, bile acid malabsorption can be 
prevalent on its own or as part of a differential diagnosis as it is coupled with several 
diseases (Klimova et al., 2015). It is often characterized by a defect in the enterohepatic 
circulation of bile acids where increased bile acids are not reabsorbed in the ileum and 
reach the colon. Another commonly used marker for bile acid malabsorption is the serum 
C4 test (7α-hydroxycholest-4-en-3-one). In patients with Crohn’s disease this is typically 
used as a surrogate marker of bile acid malabsorption and it has been reported that up to 
50% of adult patients with Crohn’s disease have bile acid malabsorption (Lenicek et al., 
2011). In humans, bile acid malabsorption occurs in patients with ileal resection, can be 
idiopathic or have a “Type 2” malabsorption with unknown etiology, or be secondary to 
various other primary diseases (e.g., chronic pancreatitis, celiac disease, small intestinal 
bacterial overgrowth and radiation enteritis) (Gothe et al., 2014).  
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In dogs with chronic diarrhea, clinical signs and therapeutic options can manifest 
themselves in numerous ways.  Inflammatory bowel disease is typically recognized as a 
disease of exclusionary efforts coupled with finally immunosuppressive drugs as a final 
course of therapeutics. Generally, however, clinicians must also provide evidence of 
histological evidence to support an etiology with inflammation present (Jergens et al., 
2003; Allenspach et al., 2007). Common therapeutic approaches include dietary trials as 
well as antimicrobial use to empirically treat disease and characterize it (Westermarck et 
al., 2005). Unfortunately, finding a causative agent to chronic diarrhea in dogs is not 
always simple nor is definitive. Given the prevalence of bile acid malabsorption in human 
chronic diarrhea patients, Kent et al. hypothesized that bile acid malabsorption may be a 
relevant disorder in dogs (Kent et al., 2016). Their study analyzed C4 concentrations in 17 
dogs with chronic diarrhea and 20 healthy control dogs, however, they found no 
significant difference between control dogs (serum C4 median [min-max]: 80.9 nmol/l 
[15.1-180.1 nmol/l]) and dogs with chronic diarrhea (serum C4 median [min-max]: 59.9 
nmol/l [21.3-518.6]; p=0.8) when evaluating C4 as a parameter for bile acid 
malabsorption. Three of the patients in this study had C4 concentrations above their 
reference interval and were noted to only partially respond to varying types of therapy. 
Our study indicated that almost 60% of dogs with CE had secondary bile acids as a percent 
of total that were below the reference interval established for healthy dogs. In the future 
this reference interval may serve as a useful tool in diagnosing bile acid dysmetabolism.  
As mentioned previously, many of these patients were treated with 
immunosuppressive drugs. Collagenous colitis in humans is characterized by 
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inflammation in the large bowel with long-standing watery diarrhea and budesonide has 
been suggested as efficacious in its treatment (Bajor et al., 2006). The proposed 
mechanism of action supported by corticosteroids used in animal models is the 
upregulation of the Apical Sodium-dependent Bile Acid Transporter (ASBT), the main 
transporter responsible for uptake of bile acids in the terminal ileum (Nowicki et al., 1997). 
Corticosteroids may stimulate the reuptake of bile acids by promoting ASBT in the ileum 
and could improve gastrointestinal health in dogs with IBD that have downregulated 
ASBT gene expression.  
Limitations of this study are that the assay used to investigate the fecal bile acid 
profile was unable to measure sulfated bile acids and conjugated bile acids. Also, studies 
in humans with IBD (Duboc et al., 2012; Duboc et al., 2013) have suggested that these 
may also play a role in the inflammatory loop. Furthermore, serum bile acids may further 
provide a systemic view into the regulation of bile acids. Currently efforts are underway 
to adapt this assay to measure bile acids in serum. One of the advantages to the assay used 
in this study is the ability to acquire results in only a couple days. This assay could be used 
as a first line of diagnostics when investigating chronic diarrhea in dogs as to assess the 
likelihood of bile acid dysmetabolism being a contributing factor in disease. If a fecal 
sample were to arrive in the morning at the laboratory, it can then be frozen at -80° C for 
several hours, lyophilized overnight, and then extracted and analyzed the following day. 
Furthermore, fecal samples offer a non-invasive diagnostic approach contributing to a 
positive experience for the patient. In addition, this assay can be performed on a simple 
gas chromatographer coupled with a mass spectrometer which comes at a fraction of the 
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price of a high mass accuracy instrument, making it a potentially affordable option for 
clients. Further, research is needed to correlate clinical outcome with fecal bile acid profile 
and the potential usefulness of sequestrants or predictive power of bile acid profiles and 
the use of corticosteroids. 
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CHAPTER IV 
LONGITUDINAL CHARACTERIZATION OF UNTARGETED FECAL 
METABOLOMICS IN DOGS WITH INFLAMMATORY BOWEL 
DISEASE	
Overview	
 The fecal metabolomic profile in dogs with IBD over time has not been previously 
described. IBD in dogs follows a general diagnostic workflow, where patients are 
sequentially trialed on novel diets, antimicrobials, and, when these fail, 
immunosuppressive therapy. Furthermore, upon biopsy, these patients must show 
evidence of intestinal inflammation. The aim of this study was to globally assess 
metabolites over time. In this study, fecal samples from patients were collected at baseline 
(prior to immunosuppressive therapy), 3 weeks, 8 weeks, and more than one year later. 
Gas chromatography coupled with mass spectrometry was used to identify and measure 
metabolites. Principal component analysis revealed separation between healthy dogs and 
dogs with IBD at baseline. Univariate analysis revealed that the most significantly altered 
metabolites were those belonging to amino acids isoleucine, proline, valine, leucine, 
threonine, serine, glycine, aspartic acid, oxoproline, alanine, and methionine (q<0.05 for 
all). Untargeted metabolomics shows differences between healthy dogs and dogs with IBD 
up to a year after initial diagnosis. 
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Introduction	
 Idiopathic inflammatory bowel disease (IBD) is thought to involve the 
inappropriate activation of the mucosal immune system with inflammatory cell infiltrates 
in the intestine (Allenspach et al., 2007). Studies have shown that there is also a microbial 
dysbiosis present in dogs with IBD along with disturbances in the serum metabolite profile 
(Suchodolski et al., 2012a; Suchodolski et al., 2012b; Minamoto et al., 2014b). 
 Untargeted metabolomics can describe biological systems and allows 
understanding of the relationship between the host and the microbiota along the 
gastrointestinal tract (Guard and Suchodolski, 2016). The benefit of untargeted 
metabolomics is the ability to, without bias, sample hundreds of metabolites and then to 
systematically create networks of pathways and associations to further better understand 
an active disease or healthy state (Xia et al., 2015). It is clear that there still remains much 
to be delineated from biological systems regarding the pathogenesis of IBD in dogs. 
Furthermore, up until this point in time, few studies have looked at fecal metabolites using 
an untargeted metabolomics platform (Honneffer et al., 2015a). Some studies have 
described serological and urinary metabolomics changes, but these may inherently miss 
the most active biological sample of disease and healthy states in the gastrointestinal tract 
of dogs (Minamoto et al., 2014b; Guard et al., 2015). 
 To date, there is no literature that describes the fecal metabolome in dogs with IBD 
over time after initial diagnosis.  Therefore, the aims of this study were to evaluate canine 
patients with IBD at initial treatment, 3 weeks post treatment, 8 weeks post treatment, and 
then more than one year after initial enrollment. Gastrointestinal function was assessed by 
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gas chromatography coupled with mass spectrometry. The goal of this study was to better 
describe and understand the pathogenesis and therapeutic effects on the fecal metabolome 
of dogs treated for IBD. 
Materials and methods	
Fecal samples from healthy dogs (n=13) were collected from pets belonging to 
personnel at Texas A&M University’s College of Veterinary Medicine and immediately 
stored at -80° C until further analysis. Dogs with inflammatory bowel disease (IBD) (n=9) 
were prospectively enrolled from Iowa State University (ISU). Similarly, fecal samples 
were collected and immediately stored at -80° C until further analysis.  Patients were 
diagnosed with IBD by a board certified veterinary internist based on the World Small 
Animal Veterinary Association (WSAVA) criteria: chronic GI signs (>3 weeks), 
histopathologic evidence of mucosal infiltration with inflammatory cells, inability to 
document other causes of GI inflammation, inadequate response to dietary, antibiotic, and 
anthelmintic therapies, and clinical response to anti-inflammatory or immunosuppressive 
agents. Fecal samples were collected from these dogs at baseline enrollment, 3 weeks post 
therapeutic intervention, 8 weeks post therapeutic intervention, and then a subset of 
samples (n=5) were followed up more than a year later.  
Fecal samples were lyophilized and approximately 10 mg was sent to the West 
Coast Metabolomics Center (WCMC) at University of California at Davis 
(http://metabolomics.ucdavis.edu/). Samples were analyzed on a gas 
chromatography/mass spectrometry platform. 
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Statistical analysis was carried out using MetaboAnalyst 3.0. Peak intensity tables 
were uploaded and underwent autoscaling for normalization. MetaboAnalyst 3.0 was used 
for multivariate analysis and data reduction. JMP Pro 12 (Cary, NC, USA) was used to 
test for normality using the Shaprio-Wilks test, and to test between multiple time points 
using the Kruskal-Wallis test with blocking where appropriate to account for repeated 
measures. The Benjamini and Hochberg False Discovery Rate was used to adjust for 
multiple comparisons. 
Results 	
 Of the 664 metabolites identified, 233 metabolites were named compounds.  
Figure 6 is a PCA score plot of all unnamed and named metabolites in the feces of 
healthy dogs and dogs with IBD at baseline, 3 weeks, 8 weeks, and more than 1 year later. 
Ellipses represent the 95% confidence interval of metabolite profiles for each group. 
While none of these groups have clear separation from one another, it can be appreciated 
that dogs with IBD at baseline, 3 weeks, and 8 weeks do not share considerable overlap 
with healthy dogs. More than 1 year later after therapy several dogs with IBD still remain 
outside of the 95% confidence interval of healthy dogs.  
 A heatmap of all named and unnamed compounds is represented in Figure 7. More 
than 1 year later after immunosuppressive treatment dogs with IBD still had 
concentrations of compounds that were unlike those of healthy dogs.  
 For univariate analysis a Kruskal-Wallis test was used to compare all named 
compounds for each group in all combinations (i.e., healthy vs. baseline vs. 3 week vs. 8 
week vs. >1 year later [LT]). Q-values represent adjusted p-values based on the Benjamini 
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and Hochberg False Discovery Rate. Eight-five named compounds were significantly 
different between groups after adjusting for multiple comparisons. These results are 
displayed in Table 6. 
  
 
 
Figure 6. Principal component analysis of all metabolites and patient groups. Shaded 
areas of color indicate 95% confidence intervals. 
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Figure 7. Heatmap of all named and unnamed metabolites in healthy dogs and dogs with 
IBD over time. 
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Table 6. Named compounds identified by untargeted metabolomics approach. 
   median (minimum‐maximum)       
Compound Name  Healthy  Baseline  3WK  8WK  LT  p‐value 
q‐
value 
isoleucine  26577(10376‐289686)  556836(294264‐1690615)  438367(67537‐924792)  494757(79849‐958678)  90876(36000‐336552)  <0.0001  0.0008 
N‐acetyl‐D‐mannosamine  882(331‐2818)  31739(3431‐164573)  15297(1684‐44299)  13339(3996‐48955)  1757(1163‐30923)  <0.0001  0.0008 
proline  23221(11811‐142383)  515475(47021‐698587)  128358(51736‐280586)  184146(24832‐547090)  40940(19356‐189587)  <0.0001  0.0008 
glycerol  7539(5223‐29787)  64110(32140‐1765705)  65627(5708‐219343)  72492(30732‐470719)  39131(10634‐47787)  <0.0001  0.0013 
glycerol‐3‐galactoside  413(343‐879)  3827(1037‐53291)  2581(379‐8372)  2441(916‐64972)  1181(264‐2117)  <0.0001  0.0015 
valine  55326(20761‐536562)  749451(337020‐2792415)  461472(80038‐895556)  611083(78449‐992207)  164748(75384‐441410)  <0.0001  0.0016 
leucine  43494(13811‐609130)  1038002(396641‐2712966) 
494919(109327‐
1506572)  812199(60812‐1202834)  153784(59713‐490046) 
<0.000
1  0.0016 
threonine  7027(2033‐17178)  82789(5234‐400823)  78011(16232‐194723)  59227(5690‐147818)  14148(8082‐57445)  0.0001  0.0017 
serine  5405(3326‐14758)  70278(11063‐486844)  55806(6596‐256332)  88199(4086‐182978)  17150(7164‐71159)  0.0001  0.0018 
glycine  11080(5897‐120523)  172487(29837‐501579)  51108(18225‐130575)  50104(19538‐242928)  33255(11443‐45668)  0.0001  0.0018 
aspartic acid  2928(1326‐5528)  35358(7619‐279780)  22165(2730‐97491)  17802(5776‐68706)  12267(2900‐30772)  0.0001  0.0018 
hypoxanthine  955(444‐2940)  22179(1342‐80813)  16713(1073‐82680)  24983(1997‐42927)  2497(849‐8800)  0.0001  0.0019 
phosphate  1568(120‐3107)  7192(2589‐31210)  3107(829‐10316)  4371(1392‐11848)  1453(356‐3351)  0.0001  0.0020 
hexuronic acid  682(226‐3622)  15788(747‐244698)  3231(863‐24216)  2108(1374‐11672)  6028(1708‐26564)  0.0001  0.0020 
oxoproline  11680(5196‐44065)  162102(34840‐748606)  59130(12016‐245911)  83169(11113‐161594)  96628(13565‐278660)  0.0001  0.0022 
alanine  208236(48686‐522481)  774432(390159‐2900922)  918172(153011‐2129205) 
1036280(214667‐
2886082)  450399(187458‐948840)  0.0002  0.0025 
methionine  2196(795‐5921)  27886(3286‐49761)  33553(843‐158744)  55474(3170‐114884)  10590(6382‐62943)  0.0002  0.0026 
ethanolamine  8733(1657‐26138)  44208(31857‐214050)  42835(5301‐103047)  36105(16667‐379372)  20975(5473‐93690)  0.0002  0.0026 
4‐hydroxybenzoate  16925(7637‐29168)  6127(1194‐48606)  2758(1220‐11802)  4395(1519‐12754)  2617(990‐3841)  0.0002  0.0026 
1‐monostearin  618(55‐1482)  3100(1240‐22869)  1984(412‐3983)  1257(282‐13565)  1604(1422‐5013)  0.0002  0.0027 
lauric acid  5560(1206‐124088)  34502(3692‐3481516)  207554(6922‐2069588)  203923(10968‐873995)  59206(5864‐152745)  0.0003  0.0028 
2‐ketoisocaproic acid  2791(1430‐4146)  6611(3283‐13668)  5025(3097‐13537)  3802(2288‐9867)  3801(2585‐4849)  0.0003  0.0028 
glutamic acid  12600(1932‐36918)  87004(18902‐671376)  38378(9905‐195461)  51121(7453‐226163)  28380(15696‐36007)  0.0003  0.0035 
myo‐inositol  725(151‐1394)  31877(463‐151492)  3854(477‐5752)  5274(432‐9667)  780(149‐182031)  0.0005  0.0045 
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Table 6. Continued. 
   median (minimum‐maximum)       
Compound Name  Healthy  Baseline  3WK  8WK  LT  p‐value 
q‐
value 
glycyl tyrosine  348(133‐1080)  2482(389‐5428)  591(311‐5720)  1382(304‐3565)  631(251‐1724)  0.0005  0.0046 
galacturonic acid  460(148‐4876)  11424(576‐204182)  7153(366‐74290)  1960(570‐13181)  5299(1578‐29560)  0.0006  0.0051 
xanthine  897(193‐10486)  3665(474‐43306)  15814(436‐72799)  15028(4569‐44507)  6756(1379‐32620)  0.0006  0.0051 
glucose  1373(433‐26551)  43808(879‐897934)  39501(1210‐1258868)  56316(7990‐1278392)  22022(1394‐392146)  0.0006  0.0052 
glyceric acid  1393(557‐5357)  4375(3323‐21877)  5700(846‐14547)  2415(1330‐41876)  4108(1527‐20551)  0.0007  0.0052 
3‐ureidopropionate  380(168‐2338)  1536(378‐29342)  1952(686‐19985)  2530(1439‐5968)  1696(1106‐3021)  0.0007  0.0052 
fructose  619(238‐2354)  10814(611‐70881)  2350(179‐45190)  5699(1636‐20497)  1127(455‐11651)  0.0007  0.0055 
tocopherol gamma‐  3259(1288‐6006)  3226(679‐43695)  9970(5341‐27474)  13945(2675‐30244)  14056(6223‐39758)  0.0008  0.0056 
ribose  4279(1477‐49192)  18391(5613‐552964)  73667(1836‐361182)  43664(25332‐96132)  29162(4163‐55537)  0.0008  0.0057 
stearic acid  223504(103989‐354253)  977125(322242‐4372844)  659264(193132‐2455396)  566598(200772‐1292419)  306946(233655‐861578)  0.0008  0.0057 
indole‐3‐lactate  53140(10285‐100744)  4920(857‐185932)  4092(652‐40125)  5636(521‐11746)  6704(255‐14597)  0.0009  0.0057 
6‐deoxyglucose  2906(1828‐30658)  27467(5401‐632255)  75744(5177‐490158)  43034(16408‐290371)  25606(5869‐102650)  0.0009  0.0057 
               
arachidonic acid  4875(481‐24715)  145437(8608‐608539)  23434(2421‐308858)  49092(4581‐610110)  23732(18841‐42727)  0.0009  0.0057 
cystine  120(81‐845)  1672(278‐9927)  408(95‐2248)  355(143‐7192)  513(177‐1509)  0.0010  0.0063 
arachidic acid  3807(857‐6403)  14601(2943‐255769)  9415(3422‐56311)  6735(1533‐16836)  5001(1049‐6960)  0.0012  0.0069 
fucose  7380(2795‐37415)  52545(5814‐895532)  42144(10371‐1002140)  66594(13939‐329459)  7615(3863‐1262224)  0.0013  0.0073 
N‐acetyl‐D‐galactosamine  1241(631‐3121)  25145(293‐86721)  5887(520‐178798)  15116(5987‐130321)  2228(910‐385457)  0.0013  0.0075 
dehydroabietic acid  727(315‐1328)  1344(972‐4654)  1144(373‐6460)  628(204‐1813)  429(370‐692)  0.0015  0.0084 
phenylalanine  45415(2748‐375944)  262770(106143‐756259)  265733(29745‐617906)  281273(77957‐575192)  92060(58615‐219988)  0.0016  0.0084 
tryptophan  33488(2989‐164489)  308541(44962‐389516)  101110(22429‐547341)  156554(20369‐587750)  165374(33302‐264007)  0.0016  0.0084 
isomaltose  390(229‐870)  1250(394‐16385)  649(254‐2984)  1241(429‐7275)  866(284‐42612)  0.0018  0.0093 
caprylic acid  995(740‐1623)  1427(1127‐2030)  1576(1094‐2947)  1331(902‐2024)  1183(991‐1614)  0.0027  0.0134 
ribonic acid  179(91‐798)  977(187‐2834)  744(141‐1596)  340(110‐1620)  944(293‐1077)  0.0027  0.0134 
aminomalonate  577(297‐5082)  7323(1104‐40505)  1670(270‐4745)  2229(270‐7073)  2061(502‐3139)  0.0029  0.0141 
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Table 6. Continued. 
   median (minimum‐maximum)       
Compound Name  Healthy  Baseline  3WK  8WK  LT  p‐value 
q‐
value 
maltose  4086(1260‐14014)  5672(3213‐92323)  36684(852‐305114)  18781(2004‐103462)  27706(10763‐368735)  0.0033  0.0156 
urocanic acid  317(112‐653)  1828(191‐5828)  1957(142‐9255)  2149(388‐18966)  566(344‐2457)  0.0035  0.0164 
pseudo uridine  1598(330‐2846)  3202(398‐7836)  4391(1056‐8884)  3224(2031‐12055)  1816(465‐4129)  0.0037  0.0167 
3‐(4‐hydroxyphenyl)propionic acid  27330(12628‐95206)  4909(193‐94230)  17485(932‐30945)  22353(915‐57023)  11254(621‐12763)  0.0038  0.0170 
nicotinic acid  8187(1182‐22197)  12122(1352‐40303)  23604(8009‐71569)  43627(12742‐65764)  17631(4723‐44494)  0.0044  0.0190 
inositol‐4‐monophosphate  179(66‐469)  740(274‐1233)  302(58‐3865)  207(127‐1282)  206(92‐676)  0.0044  0.0190 
xylulose NIST  258(89‐12652)  1737(443‐140913)  2212(581‐41182)  3373(958‐5791)  3458(584‐6148)  0.0046  0.0195 
sinapinic acid  554(107‐5910)  534(216‐1453)  284(118‐1170)  224(61‐347)  251(109‐274)  0.0050  0.0206 
nonadecanoic acid  962(425‐1889)  2520(861‐11053)  1963(896‐21054)  1579(874‐42875)  1524(1027‐3390)  0.0053  0.0217 
gluconic acid  102(47‐407)  270(92‐6789)  216(89‐540)  260(101‐13408)  181(113‐335)  0.0055  0.0219 
pinitol  140(81‐654)  1596(166‐24757)  272(76‐9589)  185(115‐1137)  2683(136‐6475)  0.0057  0.0225 
lignoceric acid  708(252‐1646)  3147(639‐18549)  1111(440‐5123)  1350(614‐2244)  1114(682‐1319)  0.0059  0.0228 
lyxitol  1115(428‐2883)  10974(648‐37592)  4168(619‐10370)  3131(1403‐18653)  5431(875‐9730)  0.0060  0.0228 
tyramine  69361(1580‐314004)  533616(63017‐2792734)  286305(29660‐1521298)  290170(23469‐660553)  99311(4259‐326182)  0.0061  0.0228 
isoheptadecanoic acid NIST  1684(628‐6892)  3801(2235‐12719)  3190(494‐7580)  4280(2218‐9118)  1539(533‐9439)  0.0064  0.0237 
beta‐gentiobiose  580(276‐5671)  4366(735‐104767)  1141(292‐34083)  1174(648‐34232)  1541(549‐36953)  0.0067  0.0245 
pentitol  224(152‐500)  729(133‐1801)  470(189‐2404)  623(282‐914)  690(432‐1947)  0.0070  0.0249 
methionine sulfoxide  8442(4675‐93493)  61977(19978‐154439)  49847(5055‐83688)  35710(5353‐47437)  11242(4504‐43917)  0.0071  0.0249 
adenosine  1633(293‐5364)  441(205‐8151)  461(81‐14435)  363(167‐1194)  979(282‐1413)  0.0074  0.0258 
oxamic acid  198(111‐445)  901(307‐1858)  286(165‐2547)  300(115‐1220)  477(181‐694)  0.0078  0.0268 
glucoheptulose  348(224‐1311)  1537(506‐11886)  471(133‐1732)  470(155‐1122)  371(212‐2059)  0.0080  0.0268 
malic acid  147(98‐307)  772(61‐3472)  830(60‐3004)  349(78‐558)  430(176‐1986)  0.0081  0.0268 
2‐hydroxyglutaric acid  320(117‐565)  1207(115‐6574)  509(192‐2042)  581(247‐43173)  554(309‐820)  0.0102  0.0326 
threonic acid  150(62‐322)  790(99‐1718)  334(108‐1145)  248(99‐567)  429(91‐3052)  0.0102  0.0326 
tagatose  135(73‐703)  678(157‐5063)  380(91‐1720)  283(155‐2210)  180(98‐645)  0.0103  0.0326 
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Table 6. Continued. 
   median (minimum‐maximum)       
Compound Name  Healthy  Baseline  3WK  8WK  LT  p‐value 
q‐
value 
lysine  24523(5879‐90749)  121540(26306‐461633)  152916(13443‐778380)  146398(7737‐957242)  41522(4552‐268191)  0.0104  0.0326 
asparagine  1026(625‐5414)  8328(1185‐29660)  1623(562‐7690)  2443(624‐13117)  3141(1073‐4127)  0.0119  0.0370 
hexitol  241(111‐446)  1053(349‐1833)  328(67‐3686)  260(117‐3527)  229(163‐815)  0.0121  0.0372 
diglycerol  2192(514‐7187)  7350(2205‐24931)  6018(246‐17619)  1526(506‐6493)  3743(837‐9240)  0.0123  0.0372 
5,6‐dihydrouracil  225(157‐3126)  972(211‐6333)  285(134‐1520)  308(113‐2962)  1857(338‐2699)  0.0134  0.0399 
n‐acetyl‐d‐hexosamine  700(231‐1877)  1581(316‐4482)  1382(391‐2286)  1045(719‐5229)  998(294‐2506)  0.0135  0.0400 
tocopherol delta‐ NIST  1089(625‐2109)  1026(434‐13065)  5363(919‐12271)  3820(993‐17238)  2145(1464‐9718)  0.0138  0.0402 
catechol  812(93‐2846)  162(77‐1914)  134(67‐639)  545(81‐1877)  150(87‐409)  0.0142  0.0409 
3,4‐dihydroxyphenylacetic acid  1599(593‐4633)  582(319‐2067)  512(101‐5080)  443(165‐1931)  398(157‐2496)  0.0149  0.0420 
3,4‐dihydroxyhydrocinnamic acid 
NIST  221409(80063‐677635)  30154(1756‐355869)  80861(1137‐273783)  36676(4273‐481152)  64810(9744‐235721)  0.0150  0.0420 
indole‐3‐acetate  8205(4345‐14470)  3371(335‐20169)  2492(664‐4459)  3483(1119‐10497)  2531(736‐9412)  0.0152  0.0422 
isothreonic acid  232(67‐1218)  957(306‐6941)  949(224‐3263)  465(121‐741)  424(280‐3836)  0.0165  0.0454 
dihydrocholesterol  3340(91‐16341)  7696(5181‐14043)  4055(211‐7939)  2918(311‐8502)  3376(1351‐5031)  0.0189  0.0512 
myristic acid  2205(291‐6739)  6148(1652‐630293)  5101(1436‐207152)  9743(1021‐114200)  2821(2011‐18287)  0.0196  0.0526 
trans‐4‐hydroxyproline  4894(1463‐102989)  12260(3496‐99723)  6137(723‐10146)  3409(1109‐16460)  7362(1248‐26102)  0.0203  0.0537 
pipecolinic acid  9241(5077‐20941)  3851(718‐31419)  4491(1478‐16133)  7968(1659‐16159)  3671(2736‐23968)  0.0215  0.0559 
pyruvic acid  951(617‐3313)  1495(533‐3768)  1131(570‐14870)  2864(1385‐4288)  2122(484‐5185)  0.0216  0.0559 
alpha‐ketoglutarate  103(64‐188)  179(82‐923)  173(70‐1819)  197(101‐410)  164(125‐352)  0.0240  0.0615 
sorbitol  1236(521‐103007)  5976(1819‐85961)  4027(1015‐152927)  4237(532‐14196)  6884(770‐19606)  0.0260  0.0658 
allantoic acid  144(57‐3731)  1543(140‐4438)  502(112‐20140)  346(161‐13606)  338(97‐15528)  0.0273  0.0683 
glycyl‐proline  2573(650‐21760)  19938(1580‐99872)  10607(1518‐33310)  11310(2222‐36831)  6786(1344‐13944)  0.0293  0.0720 
homocystine  579(124‐1315)  1829(523‐6761)  1012(203‐6055)  1151(943‐2243)  2818(323‐9392)  0.0294  0.0720 
adenine  1971(613‐5329)  11827(1257‐154122)  4694(1157‐38419)  4756(476‐76981)  2302(486‐6297)  0.0309  0.0751 
uric acid  497(99‐3729)  1294(397‐15419)  1497(254‐6040)  2746(472‐21520)  882(472‐4603)  0.0323  0.0775 
homoserine  1760(524‐5279)  3716(1434‐386718)  3157(1463‐11620)  4063(940‐71895)  7478(1943‐11920)  0.0338  0.0798 
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   median (minimum‐maximum)       
Compound Name  Healthy  Baseline  3WK  8WK  LT  p‐value 
q‐
value 
cysteine  1061(477‐6222)  7854(355‐31103)  1786(733‐7382)  1639(417‐8775)  5225(1208‐11107)  0.0339  0.0798 
orotic acid  119(41‐297)  410(131‐2249)  280(53‐4711)  219(55‐1734)  179(83‐260)  0.0356  0.0826 
pelargonic acid  10763(7384‐15788)  10561(5685‐16297)  9726(4348‐13112)  7061(4336‐11873)  7320(6645‐8963)  0.0358  0.0826 
glycerol‐alpha‐phosphate  552(123‐3542)  2049(451‐11468)  735(161‐2724)  324(128‐2943)  1222(407‐2095)  0.0389  0.0889 
phenylpyruvate  658(251‐4696)  4116(458‐93952)  2562(1069‐14066)  3944(1021‐29587)  2026(631‐11970)  0.0401  0.0907 
octadecylglycerol  7015(1838‐50345)  22552(4660‐73404)  11363(746‐36579)  27007(9116‐42427)  10906(7242‐13237)  0.0415  0.0930 
citrulline  831(376‐2446)  1586(866‐15996)  1408(404‐13847)  1998(1022‐7261)  3006(179‐5507)  0.0433  0.0961 
tyrosine  90206(8682‐639148)  375490(9478‐595405)  278472(58750‐1117954)  416541(50748‐798207)  183471(126642‐613622)  0.0451  0.0992 
2‐methylglyceric acid NIST  126(64‐4996)  5562(93‐45059)  589(77‐1733)  192(99‐2227)  2155(75‐19369)  0.0458  0.0992 
squalene  867(346‐2503)  1688(1095‐4182)  1306(791‐6627)  1597(582‐2813)  1366(788‐2019)  0.0460  0.0992 
succinic acid  633(361‐246026)  251359(371‐2131387)  14708(830‐62713)  1332(968‐44182)  79604(971‐935926)  0.0465  0.0994 
hydroquinone  1826(882‐6201)  1519(406‐5350)  1007(294‐2320)  1704(666‐3705)  751(441‐1817)  0.0474  0.1005 
behenic acid  8412(1162‐74752)  13862(9932‐184154)  12544(998‐58346)  17673(9448‐35544)  15293(8314‐54846)  0.0487  0.1022 
uridine  919(309‐2124)  2478(856‐21609)  1597(475‐7200)  1098(508‐5346)  1301(538‐2467)  0.0512  0.1059 
capric acid  562(108‐860)  737(492‐5580)  862(495‐9912)  797(185‐2432)  528(321‐1522)  0.0514  0.1059 
thymine  8572(1066‐25719)  8099(1212‐46784)  21682(1870‐42343)  30348(10109‐61035)  10790(5469‐26657)  0.0523  0.1068 
guanine  656(177‐1369)  1112(291‐8060)  845(194‐5783)  1083(231‐1463)  527(170‐690)  0.0544  0.1101 
docosahexaenoic acid  2731(1188‐17090)  15522(1519‐101773)  11159(1071‐182212)  8699(2939‐356759)  7892(2197‐17284)  0.0570  0.1144 
hexadecylglycerol NIST  2312(562‐10838)  6802(1391‐23311)  6379(603‐7524)  6353(2372‐9078)  4281(1469‐12380)  0.0592  0.1179 
3‐phenyllactic acid  761(166‐7193)  6070(259‐190888)  3351(1019‐21682)  5279(1324‐45729)  2826(389‐18694)  0.0600  0.1184 
2‐monopalmitin  1375(803‐10336)  5504(1042‐24422)  1997(1084‐27083)  2722(805‐47042)  3700(2431‐9271)  0.0607  0.1184 
alanine‐alanine  8598(1738‐31045)  30954(13689‐95906)  15925(1258‐121588)  12939(899‐117776)  25104(15419‐33897)  0.0610  0.1184 
2‐hydroxyhexanoic acid  3303(282‐17248)  26496(837‐118992)  6736(2142‐12327)  12544(2067‐43134)  5712(614‐26052)  0.0615  0.1184 
galactinol  202(115‐473)  351(160‐26777)  262(131‐1097)  278(128‐1853)  330(254‐9217)  0.0627  0.1197 
uracil  52469(1829‐116654)  33484(1693‐131318)  75439(4988‐327791)  61895(41193‐232327)  23492(8693‐80296)  0.0650  0.1231 
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Compound Name  Healthy  Baseline  3WK  8WK  LT  p‐value 
q‐
value 
heptadecanoic acid  7231(1083‐21615)  21830(4014‐89154)  12385(2640‐17983)  7544(948‐19582)  4759(2605‐29480)  0.0656  0.1233 
parabanic acid NIST  987(833‐5629)  2945(1230‐5334)  2000(725‐6473)  2056(1005‐4184)  3226(892‐4903)  0.0682  0.1272 
palmitic acid  55348(26867‐86999)  311370(41365‐859769)  157830(23974‐646985)  117410(32479‐363361)  95953(34089‐173961)  0.0724  0.1339 
conduritol‐beta‐epoxide  182(76‐868)  1077(139‐14224)  226(69‐2487)  174(84‐18049)  435(129‐1168)  0.0753  0.1382 
lactic acid  3621(1815‐759342)  150283(5940‐1911888)  39431(4403‐384602)  14429(2413‐1253987)  47534(2086‐791246)  0.0790  0.1438 
pentadecanoic acid  12887(2780‐72216)  35899(9780‐59969)  31302(2151‐42439)  29796(10968‐60885)  8108(5544‐43266)  0.0801  0.1447 
benzoic acid  4823(1241‐11550)  2907(1586‐11394)  2897(905‐5075)  4004(1868‐7058)  3200(1633‐5620)  0.0811  0.1454 
maltotriose  103(53‐963)  123(10‐10663)  232(81‐1487)  485(99‐2732)  480(141‐12341)  0.0858  0.1526 
4‐hydroxyphenylacetic acid  34153(19306‐175023)  23973(432‐128726)  19461(900‐120375)  19597(1911‐80201)  8122(2047‐20551)  0.0874  0.1543 
fumaric acid  595(456‐7608)  1629(818‐3550)  749(619‐5836)  1296(529‐6171)  1258(264‐2952)  0.0885  0.1550 
lactamide  124(84‐432)  464(88‐9514)  155(79‐647)  123(96‐1260)  270(157‐438)  0.0905  0.1573 
guanosine  218(70‐385)  762(99‐5500)  216(50‐8578)  173(84‐1183)  450(203‐548)  0.0911  0.1573 
3‐hydroxypalmitic acid  2407(553‐9762)  1536(235‐4617)  1150(97‐14567)  1367(186‐4145)  791(194‐5854)  0.0938  0.1606 
ferulic acid  332(201‐1870)  819(224‐14534)  184(104‐1157)  321(122‐791)  264(74‐458)  0.0945  0.1606 
trehalose  936(234‐7861)  3344(651‐18886)  6108(378‐67691)  4375(533‐18067)  25343(163‐79178)  0.0957  0.1616 
maleimide  897(513‐1755)  2298(575‐8173)  1576(786‐4768)  1102(727‐4672)  1326(641‐4119)  0.1020  0.1709 
UDP‐glucuronic acid  1691(531‐5580)  6595(1613‐25425)  2476(260‐4419)  1995(772‐4994)  2556(164‐4877)  0.1056  0.1749 
xylitol  352(180‐6807)  1615(476‐16179)  717(305‐4115)  757(314‐1529)  694(189‐3838)  0.1058  0.1749 
erythritol  323(111‐11143)  6300(186‐81480)  606(212‐8446)  637(321‐5912)  5085(165‐18796)  0.1087  0.1783 
ornithine  13523(5455‐46997)  38334(7382‐193909)  19505(1109‐144493)  44221(7440‐167807)  30026(8451‐75091)  0.1118  0.1821 
lithocholic acid  4950(142‐19980)  283(112‐23542)  10860(241‐42445)  5033(1065‐25907)  3085(136‐31867)  0.1138  0.1841 
kynurenic acid  413(80‐3678)  1740(214‐646033)  835(68‐30041)  1281(131‐12673)  875(145‐40649)  0.1180  0.1895 
sucrose  221(38‐3197)  671(168‐9943)  252(46‐2991)  327(118‐6792)  291(186‐1762)  0.1187  0.1895 
shikimic acid  1203(364‐6416)  2575(876‐4511)  1567(573‐5153)  1332(969‐2982)  1402(202‐3322)  0.1259  0.1996 
xylose  14438(3729‐1122928)  47923(6712‐4196861)  52045(18292‐537964)  115290(18607‐223497)  125649(11094‐215332)  0.1298  0.2044 
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Compound Name  Healthy  Baseline  3WK  8WK  LT  p‐value 
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isopentadecanoic acid  32048(4977‐174366)  52160(15672‐128146)  49218(1761‐142854)  53098(10527‐154577)  13936(11693‐43465)  0.1325  0.2062 
linolenic acid  10465(1504‐48697)  59097(4579‐272928)  5217(527‐413705)  21940(806‐151720)  4999(1210‐26144)  0.1327  0.2062 
lactitol  230(57‐2947)  1220(268‐7637)  668(92‐3495)  609(208‐4362)  2067(130‐31104)  0.1354  0.2090 
3,4‐dihydroxycinnamic acid  588(228‐1980)  918(365‐15809)  468(156‐1172)  364(162‐755)  525(159‐913)  0.1369  0.2099 
4‐hydroxybutyric acid  902(237‐1484)  1846(169‐8253)  1368(443‐2822)  1603(460‐3735)  776(159‐1481)  0.1435  0.2174 
malonic acid  206(68‐567)  401(132‐1246)  165(52‐1679)  129(67‐663)  239(114‐934)  0.1437  0.2174 
2'‐deoxyguanosine  208(80‐759)  1177(127‐3711)  536(111‐7882)  426(70‐1931)  278(162‐1036)  0.1458  0.2192 
1,5‐anhydroglucitol  440(108‐15640)  4550(209‐23703)  1222(286‐11246)  1055(156‐9916)  1955(265‐87571)  0.1477  0.2207 
1‐monopalmitin  1654(434‐16253)  8544(1542‐67121)  2576(1141‐57106)  3258(382‐23995)  2933(2004‐12950)  0.1550  0.2300 
norvaline  6691(736‐109845)  2761(526‐78353)  18704(1962‐81718)  30154(871‐85722)  13450(10948‐44730)  0.1662  0.2452 
p‐hydroxylphenyllactic acid  388(116‐2610)  579(326‐61612)  722(249‐9777)  914(343‐8940)  1154(239‐3545)  0.1923  0.2817 
3‐aminoisobutyric acid  1804(1042‐10023)  13673(715‐27112)  5508(813‐40305)  6070(564‐11009)  2224(1216‐6673)  0.2055  0.2993 
2,6‐diaminopimelic acid  645(371‐933)  792(283‐2009)  437(90‐1318)  403(190‐1855)  321(174‐820)  0.2109  0.3052 
butane‐2,3‐diol NIST  2412(885‐11694)  5770(586‐148809)  5700(1203‐40742)  7994(1960‐106684)  8086(374‐512201)  0.2145  0.3079 
cis‐gondoic acid  365(149‐524)  742(160‐33863)  753(97‐28818)  471(146‐9141)  500(217‐1663)  0.2171  0.3079 
4‐aminobutyric acid  1721(324‐4741)  19960(163‐462782)  6402(336‐132005)  4989(738‐27162)  14473(609‐49059)  0.2178  0.3079 
1‐monoolein  16510(6765‐97660)  17268(4206‐356627)  8145(1375‐47160)  11273(1444‐675160)  26760(21535‐479094)  0.2180  0.3079 
deoxycholic acid  45851(4504‐451181)  6761(536‐419961)  13244(187‐969129)  127946(2868‐1109441)  22337(1949‐451190)  0.2374  0.3333 
levoglucosan  214(130‐1949)  473(134‐7382)  559(172‐2918)  471(178‐1457)  1088(197‐21351)  0.2389  0.3333 
glutamine  1592(587‐10279)  2898(1128‐26204)  2942(410‐10476)  3859(479‐44652)  1235(546‐2099)  0.2441  0.3374 
5‐methoxytryptamine  960(263‐3243)  1736(409‐6255)  1673(501‐4925)  1635(909‐5807)  2134(599‐9904)  0.2447  0.3374 
D‐erythro‐sphingosine  12822(2395‐155273)  17906(875‐135976)  37456(3108‐96390)  53042(3774‐118992)  23178(2633‐45934)  0.2563  0.3513 
phytanic acid  829(169‐8551)  663(252‐5031)  837(194‐3399)  515(297‐3559)  347(140‐980)  0.2671  0.3622 
thymidine  334(145‐1020)  547(241‐2565)  596(173‐5889)  397(206‐1849)  393(303‐2857)  0.2677  0.3622 
digalacturonic acid  192(74‐1836)  440(164‐12098)  231(116‐6765)  193(118‐2740)  431(139‐838)  0.2703  0.3622 
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3,6‐anhydro‐D‐glucose  884(131‐3797)  1964(1552‐3898)  1782(304‐25110)  1495(134‐14212)  2536(140‐6359)  0.2705  0.3622 
3,6‐anhydro‐D‐galactose  977(338‐4212)  2127(992‐3954)  1965(402‐9738)  2079(293‐6890)  2539(615‐6606)  0.2731  0.3636 
sophorose  125(104‐1105)  268(179‐8652)  282(117‐994)  251(85‐637)  246(82‐652)  0.2784  0.3685 
N‐acetylputrescine  2328(906‐29801)  7471(1525‐62787)  3826(271‐43047)  15260(909‐24994)  5828(3410‐11448)  0.2815  0.3705 
cholesterol  203208(2112‐825533)  442353(159558‐1501585)  306624(105229‐662212)  476337(143419‐631965)  308575(102889‐507030)  0.2872  0.3759 
biphenyl  1212(617‐4296)  1373(318‐2859)  529(284‐2193)  501(349‐3191)  993(507‐2888)  0.2907  0.3783 
2,5‐dihydroxypyrazine NIST  394(206‐801)  488(286‐1170)  442(170‐597)  262(172‐580)  329(160‐746)  0.2932  0.3795 
glycolic acid  3609(1865‐7605)  2801(860‐20791)  5969(1865‐9251)  5631(1830‐7534)  4259(2389‐10490)  0.2966  0.3819 
phenylacetic acid  8667(912‐107857)  23121(444‐109914)  18969(560‐63991)  18271(2077‐80648)  3228(1380‐7571)  0.2985  0.3821 
lyxose  1489(352‐62372)  2767(1548‐212753)  4816(1088‐34247)  2923(729‐9070)  6570(854‐8628)  0.3055  0.3889 
1‐methylhydantoin  7340(3996‐16700)  3144(1125‐76475)  4429(2419‐277343)  6215(1416‐116234)  6704(1659‐7543)  0.3225  0.4062 
inosine  1063(261‐3447)  1480(96‐6354)  227(103‐13708)  279(135‐4867)  569(239‐845)  0.3225  0.4062 
tyrosol  1642(716‐5574)  1574(235‐3303)  1474(258‐3678)  2034(858‐4397)  1522(583‐1638)  0.3244  0.4064 
phytol  614(307‐2002)  951(182‐10136)  532(316‐2328)  498(275‐1720)  466(313‐893)  0.3263  0.4066 
oleamide NIST  16397(3723‐58280)  13510(384‐29668)  5280(657‐36934)  11434(344‐19938)  6680(3957‐33341)  0.3306  0.4097 
taurine  1014(129‐4841)  2144(40‐16782)  2220(197‐12032)  2884(88‐37413)  3057(506‐23154)  0.3483  0.4277 
N‐methylalanine  45310(14918‐231749)  35366(1759‐350653)  115841(12004‐248669)  208916(14713‐627338)  111799(28211‐287734)  0.3488  0.4277 
2‐monoolein  5595(1492‐32705)  8162(2563‐482697)  2848(1920‐8422)  5215(537‐177100)  7387(1630‐50786)  0.3542  0.4320 
spermidine  4547(1353‐13775)  6814(1418‐14105)  5872(1049‐24315)  6227(967‐39089)  1989(556‐13874)  0.3621  0.4394 
2,4‐diaminobutyric acid  9739(1179‐23020)  3822(128‐23069)  8589(1244‐22530)  5904(1317‐23187)  4856(822‐36419)  0.3675  0.4436 
pantothenic acid  2760(268‐10092)  2291(633‐68122)  6993(1148‐42839)  4423(211‐50687)  7227(1580‐42662)  0.3840  0.4612 
putrescine  259448(159312‐4685827)  796818(23403‐3129062)  386381(3636‐3449841)  338754(9622‐2096637)  242749(38216‐1436002)  0.3890  0.4648 
butyrolactam NIST  2630(1970‐14143)  13718(1273‐126618)  4793(848‐40635)  4242(1623‐14037)  7577(849‐18997)  0.3944  0.4689 
linoleic acid  11048(4100‐51073)  31057(4748‐333947)  14862(1637‐510828)  18067(2165‐196151)  15340(6230‐185614)  0.4311  0.5099 
cytosin  328(152‐564)  507(280‐3006)  423(126‐709)  436(127‐5434)  442(122‐895)  0.4509  0.5306 
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Table 6. Continued. 
   median (minimum‐maximum)       
Compound Name  Healthy  Baseline  3WK  8WK  LT  p‐value 
q‐
value 
2‐hydroxybutanoic acid  5113(665‐150324)  20364(863‐305963)  7180(2450‐76307)  9627(2079‐164137)  13323(591‐182282)  0.4841  0.5666 
beta‐alanine  5766(2959‐73895)  5363(800‐71313)  10805(2580‐93715)  6066(1374‐73401)  4214(612‐31828)  0.4863  0.5666 
vanillic acid  255(174‐8563)  329(144‐1463)  231(84‐2545)  307(253‐1458)  381(135‐3592)  0.4903  0.5683 
threitol  619(160‐3116)  1061(337‐3509)  887(201‐2470)  927(333‐1765)  1226(933‐5187)  0.5037  0.5810 
4‐hydroxymandelic acid  518(225‐1375)  805(309‐44458)  605(201‐1601)  723(220‐1368)  978(222‐3813)  0.5455  0.6262 
phenylethylamine  5177(1162‐117411)  37367(882‐453129)  12233(1278‐58583)  14176(2193‐61974)  16636(2557‐85168)  0.5560  0.6336 
piperidone  89938(4990‐486822)  36629(1317‐160094)  105906(7609‐218749)  98525(4707‐233442)  33001(1844‐356059)  0.5575  0.6336 
palmitoleic acid  1167(644‐3686)  6750(263‐28814)  1525(303‐30105)  1917(381‐20837)  2513(236‐4136)  0.5632  0.6370 
creatinine  6070(238‐76418)  4936(348‐90867)  2534(850‐65756)  9911(326‐29523)  9358(7313‐216444)  0.5920  0.6663 
citramalic acid  425(217‐763)  554(83‐2069)  267(108‐848)  335(151‐474)  728(268‐2225)  0.5957  0.6673 
3‐hydroxybutyric acid  2731(1472‐15939)  6071(2082‐11734)  4515(736‐12390)  3880(1502‐53108)  6046(1518‐75219)  0.6153  0.6836 
octadecanol  305(149‐678)  359(264‐605)  454(218‐568)  430(238‐939)  325(141‐647)  0.6162  0.6836 
lanosterol  130(77‐1000)  150(74‐2001)  377(84‐2165)  594(89‐1379)  450(186‐1221)  0.6601  0.7290 
propane‐1,3‐diol NIST  921(466‐6897)  1769(356‐24322)  1710(558‐7343)  1713(677‐44685)  1957(410‐2794)  0.6640  0.7298 
alpha‐aminoadipic acid  536(138‐1061)  859(102‐2867)  773(241‐1983)  585(108‐1569)  715(340‐941)  0.6713  0.7344 
beta‐sitosterol  73794(2170‐171886)  25509(3764‐250414)  22354(3394‐148996)  63939(4842‐204588)  60178(2120‐96991)  0.6879  0.7490 
oleic acid  20380(4751‐37796)  200715(4270‐538722)  46634(1339‐765518)  23921(4817‐411134)  39548(2758‐471628)  0.6968  0.7552 
lactose  411(239‐4623)  685(300‐4591)  435(234‐6179)  726(279‐3730)  789(275‐13175)  0.7143  0.7705 
N‐acetylornithine  1568(607‐5923)  3168(144‐156625)  2292(328‐4857)  2203(1191‐7260)  1154(497‐6803)  0.7200  0.7731 
7‐methylguanine NIST  1349(370‐3156)  1297(585‐4114)  1247(270‐2479)  1008(702‐2218)  1468(283‐2822)  0.7253  0.7751 
O‐acetylserine  997(482‐2402)  1161(290‐3246)  1243(458‐4570)  954(172‐3239)  1025(496‐2516)  0.7285  0.7751 
beta‐glutamic acid  189(58‐1417)  114(86‐6485)  165(121‐434)  119(106‐4278)  81(48‐1181)  0.7542  0.7988 
monomyristin  222(165‐374)  265(118‐52086)  248(125‐618)  218(115‐5146)  362(166‐535)  0.7595  0.8007 
glutaric acid  403(252‐649)  304(85‐2983)  393(198‐908)  371(153‐2191)  644(186‐948)  0.7814  0.8154 
5‐aminovaleric acid  1190039(307367‐2587727)  1046659(5666‐2380281) 
1022910(86535‐
2372618) 
1057768(199389‐
2429102) 
869805(252895‐
2883574)  0.7818  0.8154 
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Table 6. Continued. 
   median (minimum‐maximum)       
Compound Name  Healthy  Baseline  3WK  8WK  LT  p‐value 
q‐
value 
2‐deoxytetronic acid  1166(394‐9120)  977(409‐2969)  1606(420‐4391)  1131(702‐2900)  1797(525‐3872)  0.7839  0.8154 
3‐(3‐hydroxyphenyl)propionic acid  217(121‐79508)  313(102‐3365)  218(65‐15794)  294(120‐59887)  166(129‐2489)  0.8432  0.8732 
daidzein  543(94‐18663)  547(89‐13632)  3343(79‐27648)  1831(150‐30093)  1452(84‐5067)  0.8549  0.8776 
phosphoethanolamine  253(66‐686)  252(70‐1322)  206(106‐876)  183(101‐701)  279(148‐811)  0.8550  0.8776 
3‐hydroxypropionic acid  2054(1307‐13212)  3421(942‐110349)  2648(969‐12390)  2826(1168‐23771)  7484(823‐54041)  0.8695  0.8853 
hydroxylamine  44272(25032‐76223)  31807(13652‐84391)  49033(14514‐131442)  54890(14108‐96170)  41548(13110‐83278)  0.8701  0.8853 
tocopherol acetate  7631(137‐57866)  6790(378‐18747)  6658(923‐20013)  4394(203‐17357)  5559(1011‐8403)  0.9143  0.9263 
hydroxycarbamate NIST  10701(2448‐20817)  7834(2188‐17813)  8496(1645‐13676)  9771(3207‐19724)  10383(1903‐19071)  0.9222  0.9301 
tocopherol alpha‐  69464(1276‐406178)  60018(1746‐210418)  89716(15114‐228288)  122859(18719‐194586)  57494(19902‐177958)  0.9785  0.9811 
3,4‐dihydroxybenzoic acid  4009(394‐17828)  3830(445‐12743)  4289(350‐11269)  4676(923‐11401)  1782(367‐15662)  0.9811  0.9811 
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Discussion 
The purpose of this study was two-fold, with one goal being to characterize the 
fecal metabolome in dogs with inflammatory bowel disease and the second goal being to 
characterize the changes in the metabolome longitudinally. Currently there are no 
published studies that have evaluated the fecal metabolome in dogs using an untargeted 
approach, moreover, any articles that have followed up patients over the period of 1 year. 
Untargeted metabolomics may help to uncover roles of the microbiome and metabolome 
and the mechanisms involved in the onset of inflammatory bowel disease, the alterations 
during active treatment, and potential restoration during long term recovery.  
 In this study, PCA of fecal metabolites showed limited overlapping of 95% 
confidence intervals among the groups analyzed. Untargeted serum metabolite analysis in 
dogs with IBD before and after treatment (3 weeks of therapy) failed to show any 
significant changes in the global profile (Minamoto et al., 2014b). Metabolite profiles 
from the current study may hint at the idea that these metabolites are slowly starting to 
shift back to that of healthy dogs and this is evident by 8 weeks post treatment. After one 
year, multivariate analysis revealed that there were still several dogs with IBD that did not 
fall within the 95% confidence interval of healthy dogs.  
 Of the compounds identified, amino acids and derivatives thereof were 
significantly different between groups.  Furthermore, many followed a similar pattern in 
that the peak abundance in healthy dogs were less than dogs with IBD at any one time 
point measured. Some of these compounds were isoleucine, proline, valine, leucine, 
threonine, serine, glycine, aspartic acid, oxoproline, alanine, and methionine. Recent 
 74 
 
studies in Winnie mouse models of colitis have demonstrated amino acid dysregulation 
where many are either up- or down-regulated in the colitis model compared to controls  
(Robinson et al., 2016). These models are considered reflective of human IBD. Amino 
acids continue to be of interest in chronic inflammation, however, their up or down 
regulation seem to be dependent on the study and model. For instance, Robinson et al., 
reported decreased amino acids in their model of colitis, specifically reporting branched-
chain amino acids. The current study found those type of metabolites (e.g., leucine and 
isoleucine) to be significantly decreased in healthy patients compared to dogs with IBD. 
Alternatively, these fecal metabolites have been reportedly increased in human patients 
with Crohn’s disease and Ulcerative Colitis which may be indicative, similar to this study, 
of a malabsorption of amino acids in patients with IBD (Marchesi et al., 2007). Amino 
acids play a critical role in gut health. Supplementation with amino acids (e.g., arginine, 
glutamine, glutamate, leucine, and proline) can modulate gene expression, enhance 
integrity and growth of the small intestine, and can reduce body fat (Wu, 2013). 
 When PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of 
Unobserved States) (Langille et al., 2013) was used to predict functional aspects of genes 
from bacteria in Minamoto et. al., 2014, KEGG (Kyoto Encylopedia for Genes and 
Genomes) (Kanehisa et al., 2014) orthologues were found to be underrepresented in dogs 
with IBD for those belonging to amino acid metabolism. While these results are slightly 
difficult to interpret, it could be that a lack in specific bacteria essential in amino acid 
breakdown and metabolism are responsible for build-up of amino acids. Since amino acids 
can affect gene expression it could also be that amino acid dysregulation may further 
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exacerbate the host response to inflammation. Alternatively, it may be that amino acid 
metabolism refers to the production of amino acids, in which case this hypothesis could 
not be validated since this dataset set analyzed serum, not feces. 
 Another hypothesis for amino acids may be that increased systemic amino acid 
prevalence in fecal metabolites is part of the anti-inflammatory response. For instance, 
certain amino acids have been reported to increase mucin production and colonic 
protection in DSS (dextran sulfate sodium) treated rats (Faure et al., 2006). Nutritional 
supplementation of specific amino acids may possibly be considered to further encourage 
the anti-inflammatory host response in the event that naturally it cannot sustain the anti-
inflammatory response necessary to keep the gut in a healthy state. Arginine, glutamine, 
and cysteine may serve as useful amino acid candidates to regulate since they have well-
defined roles and their effect on host physiology is well understood. Arginine promotes 
the secretion of insulin, growth hormone, prolactin, and insulin-like growth factor-I. 
Glutamine provides energy for enterocytes. Cysteine is a precursor of glutathione and its 
metabolism can be greatly altered in response to infection.  
 This study provides into the long term metabolic outcome of dogs successfully 
treated for IBD. Unfortunately, it proved very difficult to follow up these patients more 
than a year later. This was mostly due to owner involvement and compliance. Future 
studies should measure fecal amino acids in healthy dogs and dogs with IBD and verify 
whether a predictive or causative link exists with modification of these metabolites and 
their pathways. 
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CHAPTER V 
THE EFFECT OF THE BILE ACID SEQUESTRANT 
CHOLESTYRAMINE ON THE MICROBIOTA AND FECAL BILE 
ACIDS IN HEALTHY DOGS	
Overview	
  Cholestyramine is a bile acid sequestrant that acts in the gastrointestinal tract by 
binding bile acids, thus preventing their reabsorption. In human patients with 
inflammatory bowel disease (IBD), cholestyramine is often used to treat individuals with 
symptoms of diarrhea. Preliminary studies in canine patients with IBD suggest that their 
fecal bile acid concentrations are altered, typified by an increase in primary bile acids and 
a decrease in secondary bile acids compared to healthy controls. The purpose of this study 
was to determine the effect of cholestyramine on the fecal bile acids profile in healthy 
dogs. 
Baseline fecal samples were collected from healthy Beagle dogs (n = 12) two 
weeks before administration of cholestyramine. Additional fecal samples were collected 
after two weeks of daily cholestyramine administration and again two weeks later after a 
washout period. All dogs were maintained on the same maintenance diet during the study 
and were fed 11.4 g/day of cholestyramine powder (8 g active ingredient) suspended in 75 
mL of water during the cholestyramine administration period. Fecal concentrations of 
primary bile acids (i.e., CA and CDCA) and secondary bile acids (i.e., LCA, DCA, 
UDCA) were evaluated using gas chromatography coupled with mass spectrometry. 
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Microbial communities were assessed using Quantitative Insights into Microbial Ecology 
(QIIME). Data were assessed for normality using the Shapiro-Wilk test and differences in 
bile acid concentrations were compared using the Friedman’s test. The Dunn’s post-test 
was used where appropriate. Statistical significance was set at p < 0.05. 
Total fUBA significantly increased after two weeks of cholestyramine 
administration (median [min-max]: 14.2 µg/mg [5.7-25.5 µg/mg]) when compared to 
baseline values (median [min-max]: 6.6 µg/mg [5.6-17.7 µg/mg]; p = 0.0062). Secondary 
fUBA were significantly increased after two weeks of cholestyramine administration 
(median [min-max]: 13.1 µg/mg [5.5-23.3 µg/mg]) when compared to baseline values 
(median [min-max]: 6.2 µg/mg [5.4-17.1 µg/mg]; p = 0.0183). There were significant 
changes in fecal microbial communities (i.e., for unweighted and weighted unifrac 
distances) of dogs administered cholestyramine according to principal coordinate analysis 
plots (PCoA), compared statistically using ANOSIM (p<0.05). 
   In conclusion, the fecal bile acids profile and microbiome is altered in healthy dogs after 
cholestyramine administration. Further studies are needed to understand the potential 
clinical utility of cholestyramine as a therapeutic option in canine patients with 
gastrointestinal disease. 
Introduction	
 Bile acid malabsorption is gaining interest as studies are beginning to find that it 
may play a role in diarrhea or loose stool conditions in humans (Watson et al., 2014). Bile 
acid malabsorption is diagnosed by the gold standard SeHCAT test. A retention of less 
than 10-15% of the tracer is indicative of bile acid malabsorption (Gothe et al., 2014). 
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Cholestyramine and colestipol are generally effective treatments of gastrointestinal 
symptoms occurring from bile acid malabsorption (Wilcox et al., 2014). Cholestyramine 
is a positively charged non-digestible resins that bind to bile acids in the form of an 
insoluble complex, that is later excreted into the feces (Scaldaferri et al., 2013). Clinically, 
in humans bile acid sequestrants have been suggested for use in treatment of primary 
hypercholesterolemia and cholestatic pruritus given their ability to lower cholesterol. 
Furthermore, there are indications for use of bile acid sequestrants in the treatment of type 
2 diabetes mellitus, metabolic syndrome, and insulin resistance (Staels and Kuipers, 
2007).  
 Cholestyramine may help treat bile acid dysmetabolism in canine patients with 
chronic diarrhea. Cholestyramine is effective in increasing bile acid concentration in feces 
and reducing plasma cholesterol in dogs (Jansen and Zanetti, 1965). Jansen and Zanetti 
reported that plasma cholesterol could be decreased in a dose dependent fashion (i.e., 1, 
3, 6, and 10 g/dog/day) using cholestyramine. That study did not differentiate between the 
bile acids measured. There is a bile acid dysmetabolism in approximately 60% of dogs 
with CE. It is unclear whether or not restoration of the fecal bile acid profile may be 
beneficial to the overall health of the canine patients with CE. Therefore, the purpose of 
this study was to characterize the effect of cholestyramine on the fecal microbiota and bile 
acids of healthy dogs using high-throughput sequencing and gas chromatography coupled 
with mass spectrometry, respectively.  
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Materials and methods	
 Healthy research colony beagle dogs (n=12) were used in this study. The mean and 
standard deviation for the age of dogs (years) was 3.17 ± 0.82, respectively. The mean and 
standard deviation for the weight of dogs (kg) was 10.35 ± 0.88, respectively. 
Cholestyramine was administered for two weeks duration at a dose of 11.4 g/day 
cholestyramine powder (8 g/day active ingredient; Cholestyramine for Oral Suspension, 
Generic Questran, Sandoz, Holzkirchen, Germany). During this study, all dogs were fed 
the same experimental diet that was formulated to meet nutritional needs recommended 
by the Association of American Feed Control Officials. Once a day feeding took place at 
approximately 8 AM to maintain body weight. The study was a randomized crossover 
design that consisted of a baseline period and two 14 day experimental periods separated 
by a 14 day washout period. 
 Unconjugated fecal bile acids were measured using a gas chromatographer coupled 
with a mass spectrometer targeting CA, CDCA, LCA, DCA, and UDCA as described 
previously in Chapter II.  
 For DNA extraction and Illumina high-throughput sequencing, approximately 100 
mg of feces was first used in the downstream process of DNA isolation according to the 
manufacturer’s instructions (PowerSoil®, Mo Bio, Carlsbad, CA, USA). Amplification of 
the 16S rRNA genes and sequencing was performed at Molecular Research DNA (MR 
DNA: http://www.mrdnalab.com, Shallowwater, TX, USA). Samples were barcoded and 
targeted using the forward primer 515F and the reverse primer 806R to amplify the V4 
region of the 16S rRNA gene.  Quantitative Insights Into Microbial Ecology (QIIME, 
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v1.8) was used for sequence processing and analysis. Raw sequences were de-multiplexed, 
de-noised, chimera removed (USEARCH 6.1) using reference based chimera checking, 
chloroplast and mitochondrial operational taxonomic unit (OTU) removed, and screened 
for quality control eliminating low quality reads using the default parameters in QIIME. 
Open OTU picking was utilized, then picked genes against the Greengenes database (v 
13.8). Unweighted unifrac distances were used to visualize microbial communities for 
before during and after cholestyramine administration. The statistical analysis method 
Analysis of Similarities (ANOSIM) was used to test for statistical differences in microbial 
communities using the software package Primer 6 (Auckland, New Zealand). Species 
richness was compared between before, during, and after cholestyramine treatment 
through the observed species, chao1, and Shannon index matrices. Furthermore, univariate 
analysis was used to compare individual bacterial groups utilizing JMP Pro 12 (Cary, NC, 
USA) to use non-parametric, repeated measures testing through implication of a blocking 
variable and a Kruskal-Wallis test (Friedman’s test equivalent). For those that were 
significantly different after adjusting for multiple comparisons using the Benjamini and 
Hochberg false discovery rate, a Dunn’s post-test was then used to identify significant 
differences (p<0.05) between individual groups.  
Results	
 For fecal bile acids, there was no significant change in concentration between 
baseline, cholestyramine, and washout in CA (median [min-max]: 0.080 µg/mg [0.040-
0.690 µg/mg], 0.100 µg/mg [0.010-1.290 µg/mg], and 0.100 µg/mg [0.020-0.240 µg/mg], 
respectively; p=0.9785), CDCA (median [min-max]: 0.260 µg/mg [0.180-0.870 µg/mg], 
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0.350 µg/mg [0.130-1.170 µg/mg], and 0.365 µg/mg [0.130-0.650 µg/mg], respectively; 
p=0.3679), LCA (median [min-max]: 3.100 µg/mg [2.390-5.930 µg/mg], 3.900 µg/mg 
[1.790-6.260 µg/mg], and 2.915 µg/mg [1.740-4.870 µg/mg], respectively; p=0.1245), 
and UDCA (median [min-max]: 0.070 µg/mg [0.010-0.250 µg/mg], 0.060 µg/mg [0.010-
0.500 µg/mg], and 0.055 µg/mg [0.020-0.310 µg/mg], respectively; p=0.9770). 
Deoxycholic acid, however, was significantly increased from baseline to after 
cholestyramine administration and after washout returned to baseline concentrations 
(median [min-max]: 3.315 µg/mg [2.630-11.02 µg/mg], 9.500 µg/mg [3.420-18.440 
µg/mg], and 4.955 µg/mg [1.980-11.660 µg/mg], respectively; p=0.0014).  
 While there was no significant difference between baseline, cholestyramine, and 
washout groups in primary fUBA (median [min-max]: 0.3550 µg/mg [0.220-1.570 
µg/mg], 0.4200 µg/mg [0.150-2.210 µg/mg], and 0.465 µg/mg [0.160-0.820 µg/mg], 
respectively; p=0.7165), there was an increase in total fUBA (median [min-max]: 6.635 
µg/mg [5.600-17.700 µg/mg], 14.250 µg/mg [5.690-25.540 µg/mg], and 8.475 µg/mg 
[3.890-17.520 µg/mg], respectively; p=0.0062) and secondary fUBA (median [min-max]: 
6.220 µg/mg [5.370-17.070] µg/mg, 13.050 µg/mg [5.540-23.330 µg/mg], and 8.025 
µg/mg [3.740-16.700 µg/mg], respectively; p=0.0183) once again increasing significantly 
from baseline to after cholestyramine administration and after washout returning to 
baseline concentrations. These results are shown in Figure 8. 
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Figure 8. Fecal bile acid concentrations and additional parameters for healthy control 
dogs before, during, and after cholestyramine administration. 
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When expressed as a percent of total bile acids measured, there was no significant 
difference between the baseline, cholestyramine, and washout in CA (median [min-max]: 
1.05% [0.57-4.99%], 0.58% [0.03-9.67%], and 0.99% [0.61-3.93%], respectively; 
p=0.4724), CDCA (median [min-max]: 3.47% [2.74-8.76%], 3.16% [1.03-7.53%], and 
3.37% [2.70-6.70%], respectively; p=0.1054), and UDCA (median [min-max]: 0.83% 
[0.11-2.19%], 0.32% [0.15-5.56%], and 0.61 [0.26-3.44], respectively; p=0.3679). 
However, LCA, as a percent of total fUBA, was significantly decreased after 
cholestyramine administration (median [min-max]: 25.87% [18.73-37.03%]) compared 
with baseline (median [min-max]: 39.88% [25.81-49.75%]; p=0.0002). Deoxycholic acid, 
as a percent of total fUBA, was significantly increased after cholestyramine administration 
(median [min-max]: 52.77% [44.01-62.87%]) compared with baseline (median [min-
max]: 65.83% [60.05-79.58%]; p=0.0023). There was no significant difference in 
secondary fUBA between baseline, cholestyramine, and washout (median [min-max]: 
95.52% [86.25-96.59%], 96.45% [83.76-98.58%], and 95.87% [89.37-96.47%], 
respectively; p=0.1054). These results are displayed in Figure 9. 
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Figure 9. Percent of fecal bile acids and additional parameters for healthy control dogs 
before, during, and after cholestyramine administration. 
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Sequences belonging to fecal samples were rarified to 52,250 for equal sampling 
depth across all samples. When comparing dogs at baseline, during cholestyramine 
administration, and after the washout, clustered separately based on unweighted 
(ANOSIM p-value and R-statistic: 0.032 and 0.082, respectively; Figure 10) and weighted 
unifrac distances (ANOSIM p-value and R-statistic: 0.001 and 0.188, respectively; Figure 
11). Pairwise comparisons using a post-test identified that in both weighted and 
unweighted unifrac distances there was a significant difference between microbial 
communities at baseline and after cholestyramine administration (p<0.05). There was no 
statistical evidence that cholestyramine administration altered species richness regardless 
of the metric that was analyzed (Figures 12-14). 
 The following are the most significant individual changes in taxonomic 
proportions. On the phylum level, the percentage of Proteobacteria was significantly 
increased in dogs after cholestyramine (median [min-max]: 6.09 [2.42-9.35]) 
administration compared to baseline (median [min-max]; q-value: 6.09 [2.42-9.35]; 
p=0.0005).   On the class level, the percentage of Clostridia was signifcaintly decreased 
in dogs after cholestyramine (median [min-max]: 40.74 [0.17-52.98]) administration 
compared to baseline (median [min-max]; q-value: 33.80 [15.31-44.77]; p=0.0003). A 
complete list of taxonomic comparisons is in Table 7. 
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Figure 10. Principal coordinate analysis plot of unweighted unifrac distances. Red, blue, 
and orange dogs represent the microbial communities of dogs before, during, and after 
cholestyramine administration, respectively.  
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Figure 11. Principal coordinate analysis plot of weighted unifrac distances. Red, blue, 
and orange dogs represent the microbial communities of dogs before, during, and after 
cholestyramine administration, respectively. 
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Figure 12. Rarefaction curve of the alpha diversity measure observed species. Red, blue, 
and orange lines represent the species richness of dogs before, during, and after 
cholestyramine administration, respectively. 
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Figure 13. Rarefaction curve of the alpha diversity measure Shannon Index. Red, blue, 
and orange lines represent the species richness of dogs before, during, and after 
cholestyramine administration, respectively. 
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Figure 14. Rarefaction curve of the alpha diversity measure chao1. Red, blue, and orange 
lines represent the species richness of dogs before, during, and after cholestyramine 
administration, respectively. 
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Table 7. Taxonomic changes before, during, and after cholestyramine administration. 
  median (minumum‐maximum)       
Taxa  Baseline  Cholestyramine  Washout  p‐value  q‐value 
p__Proteobacteria  2.75(0.03‐7.36)  6.09(2.42‐9.35)  3.19(1.64‐12.25)  0.0001  0.0005 
p__Bacteroidetes  11.76(0.21‐20.81)  14.54(8.43‐35.87)  9.26(3.70‐15.92)  0.0081  0.0284 
p__Actinobacteria  2.05(0.12‐11.59)  1.55(0.60‐6.76)  2.15(0.90‐14.65)  0.0835  0.1949 
p__Fusobacteria  22.69(0.22‐32.78)  15.60(12.39‐30.58)  21.81(11.23‐38.15)  0.2056  0.3598 
p__Firmicutes  51.95(0.43‐75.92)  57.67(41.94‐65.01)  63.50(37.70‐74.02)  0.7290  0.8788 
p__Tenericutes  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.7881  0.8788 
p__Deferribacteres  0.01(0.00‐0.04)  0.00(0.00‐0.06)  0.02(0.00‐0.05)  0.8788  0.8788 
 
p__Firmicutes|c__Clostridia  40.47(0.17‐52.98)  33.80(15.31‐44.77)  38.42(21.54‐57.71)  <0.0001  0.0003 
p__Proteobacteria|c__Betaproteobacteria  1.29(0.02‐2.42)  3.40(0.53‐8.28)  1.61(0.54‐5.59)  0.0002  0.0015 
p__Actinobacteria|c__Coriobacteriia  1.26(0.01‐3.34)  0.95(0.11‐2.10)  1.55(0.08‐3.12)  0.0014  0.0057 
p__Bacteroidetes|c__Bacteroidia  11.76(0.21‐20.81)  14.54(8.43‐35.87)  9.26(3.70‐15.92)  0.0081  0.0244 
p__Firmicutes|c__Bacilli  6.42(0.07‐47.36)  19.98(2.71‐49.04)  14.09(1.37‐40.57)  0.0406  0.0973 
p__Proteobacteria|c__Epsilonproteobacteria  0.01(0.00‐0.09)  0.03(0.00‐0.10)  0.01(0.00‐0.09)  0.0967  0.1934 
p__Proteobacteria|c__Gammaproteobacteria  0.96(0.01‐5.90)  2.46(0.33‐7.02)  1.02(0.36‐10.01)  0.1843  0.3084 
p__Fusobacteria|c__Fusobacteriia  22.69(0.22‐32.78)  15.60(12.39‐30.58)  21.81(11.23‐38.15)  0.2056  0.3084 
p__Actinobacteria|c__Actinobacteria  0.05(0.03‐10.58)  0.05(0.03‐6.42)  0.06(0.04‐13.33)  0.4529  0.6039 
p__Firmicutes|c__Erysipelotrichi  2.33(0.19‐18.64)  2.53(0.53‐13.05)  2.69(0.36‐10.45)  0.7524  0.8598 
p__Tenericutes|c__Mollicutes  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.7881  0.8598 
p__Deferribacteres|c__Deferribacteres  0.01(0.00‐0.04)  0.00(0.00‐0.06)  0.02(0.00‐0.05)  0.8788  0.8788 
 
p__Firmicutes|c__Clostridia|o__Clostridiales  40.47(0.17‐52.98)  33.80(15.31‐44.77)  38.42(21.54‐57.71)  <0.0001  0.0005 
p__Proteobacteria|c__Betaproteobacteria|o__Burkholderiales  1.29(0.02‐2.42)  3.40(0.53‐8.28)  1.61(0.54‐5.59)  0.0002  0.0020 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales  1.26(0.01‐3.34)  0.95(0.11‐2.10)  1.55(0.08‐3.12)  0.0014  0.0076 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales  11.76(0.21‐20.81)  14.54(8.43‐35.87)  9.26(3.70‐15.92)  0.0081  0.0325 
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Table 7. Continued. 
  median (minumum‐maximum)       
Taxa  Baseline  Cholestyramine  Washout  p‐value  q‐value 
p__Firmicutes|c__Bacilli|Other  0.00(0.00‐0.00)  0.00(0.00‐0.00)  0.00(0.00‐0.00)  0.0128  0.0411 
p__Firmicutes|c__Bacilli|o__Lactobacillales  2.29(0.06‐46.94)  19.35(1.29‐48.58)  9.86(0.60‐35.97)  0.0267  0.0711 
p__Firmicutes|c__Bacilli|o__Turicibacterales  1.53(0.02‐9.62)  1.62(0.25‐8.37)  3.32(0.26‐7.97)  0.0385  0.0880 
p__Actinobacteria|c__Actinobacteria|o__Actinomycetales  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.00(0.00‐0.02)  0.0794  0.1547 
p__Proteobacteria|c__Gammaproteobacteria|o__Enterobacteriales  0.07(0.00‐5.02)  0.46(0.05‐6.74)  0.13(0.03‐9.70)  0.0870  0.1547 
p__Proteobacteria|c__Epsilonproteobacteria|o__Campylobacterales  0.01(0.00‐0.09)  0.03(0.00‐0.10)  0.01(0.00‐0.09)  0.0967  0.1547 
p__Fusobacteria|c__Fusobacteriia|o__Fusobacteriales  22.69(0.22‐32.78)  15.60(12.39‐30.58)  21.81(11.23‐38.15)  0.2056  0.2991 
p__Proteobacteria|c__Gammaproteobacteria|o__Aeromonadales  0.78(0.01‐1.54)  0.73(0.15‐4.00)  0.84(0.31‐2.47)  0.4071  0.5428 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales  2.33(0.19‐18.64)  2.53(0.53‐13.05)  2.69(0.36‐10.45)  0.7524  0.9144 
p__Actinobacteria|c__Actinobacteria|o__Bifidobacteriales  0.05(0.03‐10.57)  0.04(0.02‐6.41)  0.05(0.03‐13.32)  0.8559  0.9144 
p__Deferribacteres|c__Deferribacteres|o__Deferribacterales  0.01(0.00‐0.04)  0.00(0.00‐0.06)  0.02(0.00‐0.05)  0.8788  0.9144 
p__Tenericutes|c__Mollicutes|o__Anaeroplasmatales  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.9144  0.9144 
 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae  19.15(0.09‐31.66)  14.44(6.94‐29.30)  19.45(12.59‐31.35)  0.0001  0.0023 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae  9.12(0.11‐12.43)  13.46(6.18‐25.93)  6.30(3.63‐12.76)  0.0001  0.0023 
p__Proteobacteria|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae  1.29(0.02‐2.42)  3.40(0.53‐8.28)  1.61(0.54‐5.59)  0.0002  0.0026 
p__Firmicutes|c__Clostridia|o__Clostridiales|Other  0.02(0.00‐0.04)  0.01(0.00‐0.03)  0.03(0.01‐0.06)  0.0003  0.0026 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Veillonellaceae  1.99(0.02‐4.82)  0.97(0.28‐1.57)  2.08(0.09‐4.43)  0.0007  0.0043 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae  1.26(0.01‐3.34)  0.95(0.11‐2.10)  1.55(0.08‐3.12)  0.0014  0.0079 
p__Firmicutes|c__Bacilli|o__Lactobacillales|f__Streptococcaceae  0.38(0.00‐30.38)  6.09(0.46‐22.38)  1.38(0.18‐29.51)  0.0049  0.0221 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae  0.04(0.00‐0.31)  0.01(0.00‐0.07)  0.02(0.00‐0.21)  0.0054  0.0221 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae  12.44(0.04‐17.62)  9.58(4.43‐20.09)  12.49(5.12‐21.08)  0.0060  0.0221 
p__Actinobacteria|c__Actinobacteria|o__Actinomycetales|f__Actinomycetaceae  0.00(0.00‐0.01)  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.0083  0.0274 
p__Firmicutes|c__Bacilli|Other|Other  0.00(0.00‐0.00)  0.00(0.00‐0.00)  0.00(0.00‐0.00)  0.0128  0.0385 
p__Actinobacteria|c__Actinobacteria|o__Actinomycetales|f__Microbacteriaceae  0.00(0.00‐0.01)  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.0383  0.0977 
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Table 7. Continued. 
  median (minumum‐maximum)       
Taxa  Baseline  Cholestyramine  Washout  p‐value  q‐value 
p__Firmicutes|c__Bacilli|o__Turicibacterales|f__Turicibacteraceae  1.53(0.02‐9.62)  1.62(0.25‐8.37)  3.32(0.26‐7.97)  0.0385  0.0977 
p__Proteobacteria|c__Gammaproteobacteria|o__Enterobacteriales|f__Enterobacteriaceae  0.07(0.00‐5.02)  0.46(0.05‐6.74)  0.13(0.03‐9.70)  0.0870  0.1994 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Peptococcaceae  0.49(0.00‐1.74)  0.15(0.03‐1.57)  0.57(0.03‐2.90)  0.0946  0.1994 
p__Proteobacteria|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae  0.01(0.00‐0.09)  0.03(0.00‐0.10)  0.01(0.00‐0.09)  0.0967  0.1994 
p__Fusobacteria|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae  22.69(0.22‐32.78)  15.60(12.39‐30.58)  21.81(11.23‐38.15)  0.2056  0.3991 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__[Paraprevotellaceae]  2.66(0.04‐4.96)  1.18(0.07‐6.87)  1.85(0.04‐3.56)  0.2445  0.4483 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae  0.64(0.01‐4.18)  0.02(0.01‐4.85)  0.22(0.02‐2.30)  0.3037  0.5274 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__[Odoribacteraceae]  0.00(0.00‐0.04)  0.00(0.00‐0.02)  0.00(0.00‐0.03)  0.3764  0.6210 
p__Proteobacteria|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae  0.78(0.01‐1.54)  0.73(0.15‐4.00)  0.84(0.31‐2.47)  0.4071  0.6398 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Peptostreptococcaceae  0.43(0.00‐0.90)  0.41(0.11‐1.68)  0.50(0.19‐3.23)  0.4625  0.6938 
p__Firmicutes|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae  1.75(0.05‐29.12)  9.37(0.32‐26.20)  3.34(0.41‐27.05)  0.5061  0.7262 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__  0.00(0.00‐0.29)  0.00(0.00‐0.30)  0.00(0.00‐0.31)  0.6007  0.8259 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae  2.33(0.19‐18.64)  2.53(0.53‐13.05)  2.69(0.36‐10.45)  0.7524  0.9501 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__  0.41(0.00‐0.73)  0.38(0.22‐0.64)  0.45(0.16‐1.11)  0.7959  0.9501 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__S24‐7  0.21(0.02‐3.61)  0.03(0.01‐2.49)  0.29(0.00‐1.52)  0.8251  0.9501 
p__Actinobacteria|c__Actinobacteria|o__Bifidobacteriales|f__Bifidobacteriaceae  0.05(0.03‐10.57)  0.04(0.02‐6.41)  0.05(0.03‐13.32)  0.8559  0.9501 
p__Deferribacteres|c__Deferribacteres|o__Deferribacterales|f__Deferribacteraceae  0.01(0.00‐0.04)  0.00(0.00‐0.06)  0.02(0.00‐0.05)  0.8788  0.9501 
p__Tenericutes|c__Mollicutes|o__Anaeroplasmatales|f__Anaeroplasmataceae  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.9144  0.9501 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae  2.32(0.01‐3.96)  2.11(1.09‐5.35)  2.21(0.54‐3.74)  0.9194  0.9501 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__[Mogibacteriaceae]  0.01(0.00‐0.04)  0.01(0.00‐0.07)  0.01(0.00‐0.03)  0.9213  0.9501 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Eubacteriaceae  0.00(0.00‐0.04)  0.00(0.00‐0.04)  0.00(0.00‐0.03)  0.9857  0.9857 
 
p__Fusobacteria|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|Other  0.56(0.00‐0.85)  0.21(0.09‐0.57)  0.42(0.14‐0.67)  <0.0001  0.0003 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|Other  14.12(0.06‐27.31)  9.88(4.01‐24.37)  14.80(9.95‐26.31)  <0.0001  0.0007 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Slackia  0.05(0.00‐0.11)  0.01(0.00‐0.09)  0.05(0.00‐0.14)  <0.0001  0.0007 
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Table 7. Continued. 
  median (minumum‐maximum)       
Taxa  Baseline  Cholestyramine  Washout  p‐value  q‐value 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|g__Ruminococcus  0.01(0.00‐0.03)  0.00(0.00‐0.01)  0.01(0.00‐0.04)  0.0001  0.0015 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|g__  0.83(0.01‐1.40)  0.44(0.22‐0.79)  0.79(0.18‐1.84)  0.0001  0.0015 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides  9.12(0.11‐12.43)  13.46(6.18‐25.93)  6.30(3.63‐12.76)  0.0001  0.0015 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Catenibacterium  0.30(0.00‐1.54)  0.05(0.01‐1.08)  0.23(0.01‐0.84)  0.0002  0.0020 
p__Proteobacteria|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae|g__Sutterella  1.29(0.02‐2.42)  3.40(0.53‐8.28)  1.61(0.54‐5.59)  0.0002  0.0020 
p__Firmicutes|c__Clostridia|o__Clostridiales|Other|Other  0.02(0.00‐0.04)  0.01(0.00‐0.03)  0.03(0.01‐0.06)  0.0003  0.0022 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Blautia  7.23(0.02‐11.12)  5.26(1.53‐8.21)  6.67(2.46‐13.29)  0.0005  0.0031 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|g__SMB53  0.10(0.00‐0.17)  0.08(0.03‐0.15)  0.12(0.06‐0.19)  0.0006  0.0033 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__[Ruminococcus]  1.13(0.01‐1.98)  0.74(0.30‐1.85)  1.18(0.48‐2.63)  0.0013  0.0062 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Veillonellaceae|g__Megamonas  0.85(0.01‐3.10)  0.06(0.02‐0.62)  0.80(0.04‐2.26)  0.0013  0.0062 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Coprococcus  0.06(0.00‐0.10)  0.04(0.01‐0.11)  0.05(0.02‐0.11)  0.0014  0.0062 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella  1.20(0.01‐3.27)  0.91(0.09‐2.00)  1.52(0.03‐3.02)  0.0029  0.0123 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Veillonellaceae|g__Phascolarctobacterium  1.06(0.01‐1.99)  0.80(0.23‐1.55)  1.33(0.04‐3.04)  0.0044  0.0167 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|g__Oscillospira  0.03(0.00‐0.09)  0.01(0.01‐0.02)  0.02(0.01‐0.08)  0.0045  0.0167 
p__Firmicutes|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus  0.38(0.00‐30.38)  6.09(0.46‐22.38)  1.38(0.18‐29.50)  0.0049  0.0168 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Dorea  1.91(0.01‐2.68)  1.75(0.66‐3.70)  2.33(1.04‐3.32)  0.0051  0.0168 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Parabacteroides  0.04(0.00‐0.31)  0.01(0.00‐0.07)  0.02(0.00‐0.21)  0.0054  0.0170 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|g__  1.84(0.02‐3.14)  1.80(0.99‐3.15)  2.01(1.67‐4.20)  0.0082  0.0238 
p__Actinobacteria|c__Actinobacteria|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces  0.00(0.00‐0.01)  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.0083  0.0238 
p__Firmicutes|c__Bacilli|Other|Other|Other  0.00(0.00‐0.00)  0.00(0.00‐0.00)  0.00(0.00‐0.00)  0.0128  0.0352 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Coprobacillus  0.04(0.00‐0.16)  0.02(0.00‐0.15)  0.05(0.01‐0.21)  0.0168  0.0440 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|g__Clostridium  1.12(0.00‐4.04)  1.89(0.47‐10.19)  1.34(0.34‐6.89)  0.0259  0.0654 
p__Fusobacteria|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Cetobacterium  0.00(0.00‐0.01)  0.00(0.00‐0.04)  0.00(0.00‐0.04)  0.0332  0.0805 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__  0.25(0.00‐0.62)  0.16(0.05‐1.50)  0.33(0.08‐0.81)  0.0381  0.0836 
p__Actinobacteria|c__Actinobacteria|o__Actinomycetales|f__Microbacteriaceae|g__Leucobacter  0.00(0.00‐0.01)  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.0383  0.0836 
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Table 7. Continued. 
  median (minumum‐maximum)       
Taxa  Baseline  Cholestyramine  Washout  p‐value  q‐value 
p__Firmicutes|c__Bacilli|o__Turicibacterales|f__Turicibacteraceae|g__Turicibacter  1.53(0.02‐9.62)  1.62(0.25‐8.37)  3.32(0.26‐7.97)  0.0385  0.0836 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|g__Faecalibacterium  1.60(0.00‐2.90)  1.63(0.60‐4.46)  1.20(0.32‐2.40)  0.0477  0.1002 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Veillonellaceae|g__Veillonella  0.00(0.00‐0.15)  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.0521  0.1058 
p__Proteobacteria|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter  0.01(0.00‐0.08)  0.02(0.00‐0.10)  0.01(0.00‐0.08)  0.0608  0.1198 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__[Paraprevotellaceae]|g__[Prevotella]  1.80(0.03‐3.88)  0.33(0.04‐3.52)  1.50(0.03‐2.99)  0.0682  0.1302 
p__Proteobacteria|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__  0.00(0.00‐0.00)  0.00(0.00‐0.00)  0.00(0.00‐0.00)  0.0746  0.1383 
p__Proteobacteria|c__Gammaproteobacteria|o__Enterobacteriales|f__Enterobacteriaceae|g__  0.07(0.00‐5.02)  0.46(0.05‐6.74)  0.13(0.03‐9.70)  0.0870  0.1567 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__  0.70(0.00‐1.11)  0.55(0.30‐1.26)  0.69(0.23‐1.44)  0.0916  0.1603 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Peptococcaceae|g__Peptococcus  0.49(0.00‐1.74)  0.15(0.03‐1.57)  0.57(0.03‐2.90)  0.0946  0.1611 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Peptostreptococcaceae|Other  0.06(0.00‐0.29)  0.08(0.03‐1.12)  0.08(0.03‐2.02)  0.1011  0.1676 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__[Eubacterium]  0.36(0.00‐1.76)  0.41(0.06‐3.38)  0.22(0.03‐1.57)  0.1664  0.2688 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__[Paraprevotellaceae]|g__CF231  0.50(0.00‐1.14)  0.69(0.02‐3.27)  0.38(0.01‐1.22)  0.1773  0.2793 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__  0.00(0.00‐0.20)  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.1915  0.2943 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Epulopiscium  0.00(0.00‐0.01)  0.00(0.00‐0.72)  0.00(0.00‐0.08)  0.2245  0.3367 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|Other  0.66(0.00‐2.31)  0.84(0.20‐6.18)  0.55(0.15‐3.00)  0.2431  0.3561 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Roseburia  0.00(0.00‐0.01)  0.01(0.00‐0.03)  0.00(0.00‐0.01)  0.2569  0.3665 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Allobaculum  0.72(0.18‐18.34)  0.35(0.08‐12.81)  1.21(0.09‐10.05)  0.2658  0.3665 
p__Fusobacteria|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium  22.11(0.21‐32.09)  15.31(12.18‐30.46)  21.27(10.89‐37.49)  0.2676  0.3665 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella  0.64(0.01‐4.18)  0.02(0.01‐4.85)  0.22(0.02‐2.30)  0.3037  0.4064 
p__Proteobacteria|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae|g__  0.01(0.00‐0.09)  0.02(0.00‐0.13)  0.01(0.00‐0.05)  0.3096  0.4064 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__[Odoribacteraceae]|g__Odoribacter  0.00(0.00‐0.04)  0.00(0.00‐0.02)  0.00(0.00‐0.03)  0.3764  0.4839 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|Other  0.09(0.00‐0.29)  0.08(0.02‐0.14)  0.10(0.01‐0.18)  0.3906  0.4921 
p__Proteobacteria|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae|g__Anaerobiospirillum  0.77(0.01‐1.50)  0.72(0.14‐3.89)  0.83(0.27‐2.46)  0.4382  0.5413 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Adlercreutzia  0.01(0.00‐0.04)  0.00(0.00‐0.04)  0.00(0.00‐0.02)  0.5015  0.6016 
p__Firmicutes|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus  1.75(0.05‐29.12)  9.37(0.32‐26.20)  3.34(0.41‐27.05)  0.5061  0.6016 
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Table 7. Continued. 
  median (minumum‐maximum)       
Taxa  Baseline  Cholestyramine  Washout  p‐value  q‐value 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__|g__  0.00(0.00‐0.29)  0.00(0.00‐0.30)  0.00(0.00‐0.31)  0.6007  0.7008 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Peptostreptococcaceae|g__  0.34(0.00‐0.76)  0.32(0.08‐1.32)  0.40(0.16‐1.22)  0.7823  0.8906 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__|g__  0.41(0.00‐0.73)  0.38(0.22‐0.64)  0.45(0.16‐1.11)  0.7959  0.8906 
p__Tenericutes|c__Mollicutes|o__Anaeroplasmatales|f__Anaeroplasmataceae|Other  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.8058  0.8906 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__S24‐7|g__  0.21(0.02‐3.61)  0.03(0.01‐2.49)  0.29(0.00‐1.52)  0.8251  0.8963 
p__Actinobacteria|c__Actinobacteria|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium  0.05(0.03‐10.57)  0.04(0.02‐6.41)  0.05(0.03‐13.32)  0.8559  0.9139 
p__Deferribacteres|c__Deferribacteres|o__Deferribacterales|f__Deferribacteraceae|g__Mucispirillum  0.01(0.00‐0.04)  0.00(0.00‐0.06)  0.02(0.00‐0.05)  0.8788  0.9228 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__[Mogibacteriaceae]|g__  0.01(0.00‐0.04)  0.01(0.00‐0.07)  0.01(0.00‐0.03)  0.9213  0.9515 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Eubacteriaceae|g__Pseudoramibacter_Eubacterium  0.00(0.00‐0.04)  0.00(0.00‐0.04)  0.00(0.00‐0.03)  0.9577  0.9732 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__[Paraprevotellaceae]|g__  0.01(0.00‐0.04)  0.01(0.01‐0.08)  0.01(0.00‐0.02)  0.9828  0.9828 
 
p__Fusobacteria|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|Other|Other  0.56(0.00‐0.85)  0.21(0.09‐0.57)  0.42(0.14‐0.67)  <0.0001  0.0004 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|Other|Other  14.12(0.06‐27.31)  9.88(4.01‐24.37)  14.80(9.95‐26.31)  <0.0001  0.0007 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Blautia|s__  3.51(0.01‐7.13)  2.30(0.70‐3.40)  3.87(0.85‐8.25)  <0.0001  0.0007 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Slackia|s__  0.05(0.00‐0.11)  0.01(0.00‐0.09)  0.05(0.00‐0.14)  <0.0001  0.0007 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|g__Ruminococcus|s__  0.01(0.00‐0.03)  0.00(0.00‐0.01)  0.01(0.00‐0.04)  0.0001  0.0016 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|g__|s__  0.83(0.01‐1.40)  0.44(0.22‐0.79)  0.79(0.18‐1.84)  0.0001  0.0016 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__  9.02(0.11‐12.35)  13.38(6.12‐25.87)  6.16(3.63‐12.70)  0.0001  0.0016 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Catenibacterium|s__  0.30(0.00‐1.54)  0.05(0.01‐1.08)  0.23(0.01‐0.84)  0.0002  0.0022 
p__Proteobacteria|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae|g__Sutterella|s__  1.29(0.02‐2.42)  3.40(0.53‐8.28)  1.61(0.54‐5.59)  0.0002  0.0022 
p__Firmicutes|c__Clostridia|o__Clostridiales|Other|Other|Other  0.02(0.00‐0.04)  0.01(0.00‐0.03)  0.03(0.01‐0.06)  0.0003  0.0025 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|g__Clostridium|s__hiranonis  0.04(0.00‐0.07)  0.03(0.01‐0.05)  0.04(0.03‐0.07)  0.0003  0.0025 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|g__SMB53|s__  0.10(0.00‐0.17)  0.08(0.03‐0.15)  0.12(0.06‐0.19)  0.0006  0.0038 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella|s__stercoris  1.11(0.01‐3.12)  0.82(0.09‐1.89)  1.44(0.03‐2.81)  0.0011  0.0070 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Veillonellaceae|g__Megamonas|s__  0.85(0.01‐3.10)  0.06(0.02‐0.62)  0.80(0.04‐2.26)  0.0013  0.0073 
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Table 7. Continued. 
  median (minumum‐maximum)       
Taxa  Baseline  Cholestyramine  Washout  p‐value  q‐value 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Coprococcus|s__  0.06(0.00‐0.10)  0.04(0.01‐0.11)  0.05(0.02‐0.11)  0.0014  0.0073 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__[Ruminococcus]|s__gnavus  1.05(0.01‐1.88)  0.67(0.25‐1.77)  1.12(0.43‐2.49)  0.0017  0.0083 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__[Ruminococcus]|s__  0.07(0.00‐0.24)  0.05(0.03‐0.17)  0.07(0.04‐0.21)  0.0024  0.0112 
p__Actinobacteria|c__Actinobacteria|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces|s__  0.00(0.00‐0.01)  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.0037  0.0163 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Veillonellaceae|g__Phascolarctobacterium|s__  1.06(0.01‐1.99)  0.80(0.23‐1.55)  1.33(0.04‐3.04)  0.0044  0.0181 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|g__Oscillospira|s__  0.03(0.00‐0.09)  0.01(0.01‐0.02)  0.02(0.01‐0.08)  0.0045  0.0181 
p__Firmicutes|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__  0.38(0.00‐30.32)  6.07(0.45‐22.33)  1.37(0.18‐29.46)  0.0049  0.0181 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Dorea|s__  1.91(0.01‐2.68)  1.75(0.66‐3.70)  2.33(1.04‐3.32)  0.0051  0.0181 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Parabacteroides|s__  0.04(0.00‐0.31)  0.01(0.00‐0.07)  0.02(0.00‐0.21)  0.0054  0.0181 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|g__Clostridium|Other  0.72(0.00‐3.48)  1.47(0.27‐9.57)  0.67(0.21‐6.07)  0.0054  0.0181 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Blautia|Other  0.05(0.00‐0.10)  0.03(0.01‐0.07)  0.04(0.01‐0.13)  0.0058  0.0187 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|g__|s__  1.84(0.02‐3.14)  1.80(0.99‐3.15)  2.01(1.67‐4.20)  0.0082  0.0251 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Blautia|s__producta  2.97(0.01‐5.86)  2.55(0.83‐4.89)  2.84(1.32‐6.77)  0.0098  0.0291 
p__Firmicutes|c__Bacilli|Other|Other|Other|Other  0.00(0.00‐0.00)  0.00(0.00‐0.00)  0.00(0.00‐0.00)  0.0128  0.0367 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Coprobacillus|s__  0.04(0.00‐0.16)  0.02(0.00‐0.15)  0.05(0.01‐0.21)  0.0168  0.0463 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__[Eubacterium]|s__  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.00(0.00‐0.00)  0.0274  0.0692 
p__Firmicutes|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__ruminis  0.01(0.00‐1.34)  0.01(0.00‐0.05)  0.01(0.00‐0.03)  0.0276  0.0692 
p__Fusobacteria|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Cetobacterium|s__somerae  0.00(0.00‐0.01)  0.00(0.00‐0.04)  0.00(0.00‐0.04)  0.0277  0.0692 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella|s__  0.07(0.00‐0.16)  0.05(0.00‐0.16)  0.09(0.00‐0.21)  0.0326  0.0790 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__|s__  0.25(0.00‐0.62)  0.16(0.05‐1.50)  0.33(0.08‐0.81)  0.0381  0.0855 
p__Actinobacteria|c__Actinobacteria|o__Actinomycetales|f__Microbacteriaceae|g__Leucobacter|s__  0.00(0.00‐0.01)  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.0383  0.0855 
p__Firmicutes|c__Bacilli|o__Turicibacterales|f__Turicibacteraceae|g__Turicibacter|s__  1.53(0.02‐9.62)  1.62(0.25‐8.37)  3.32(0.26‐7.97)  0.0385  0.0855 
p__Firmicutes|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|Other  0.00(0.00‐0.04)  0.01(0.00‐0.05)  0.00(0.00‐0.04)  0.0461  0.0997 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|g__Faecalibacterium|s__prausnitzii  1.60(0.00‐2.89)  1.62(0.60‐4.45)  1.19(0.32‐2.40)  0.0477  0.1004 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Veillonellaceae|g__Veillonella|s__  0.00(0.00‐0.15)  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.0521  0.1068 
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Table 7. Continued. 
  median (minumum‐maximum)       
Taxa  Baseline  Cholestyramine  Washout  p‐value  q‐value 
p__Proteobacteria|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter|s__  0.01(0.00‐0.08)  0.02(0.00‐0.10)  0.01(0.00‐0.08)  0.0608  0.1217 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__[Paraprevotellaceae]|g__[Prevotella]|s__  1.80(0.03‐3.88)  0.33(0.04‐3.52)  1.50(0.03‐2.99)  0.0682  0.1331 
p__Proteobacteria|c__Gammaproteobacteria|o__Enterobacteriales|f__Enterobacteriaceae|g__|s__  0.07(0.00‐5.02)  0.46(0.05‐6.74)  0.13(0.03‐9.70)  0.0870  0.1658 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__|s__  0.70(0.00‐1.11)  0.55(0.30‐1.26)  0.69(0.23‐1.44)  0.0916  0.1704 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Peptococcaceae|g__Peptococcus|s__  0.49(0.00‐1.74)  0.15(0.03‐1.57)  0.57(0.03‐2.90)  0.0946  0.1720 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Peptostreptococcaceae|Other|Other  0.06(0.00‐0.29)  0.08(0.03‐1.12)  0.08(0.03‐2.02)  0.1011  0.1797 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__[Eubacterium]|s__biforme  0.36(0.00‐1.75)  0.40(0.05‐3.38)  0.21(0.02‐1.56)  0.1098  0.1909 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__[Eubacterium]|s__dolichum  0.01(0.00‐0.12)  0.01(0.00‐0.07)  0.01(0.00‐0.01)  0.1135  0.1932 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__[Paraprevotellaceae]|g__CF231|s__  0.50(0.00‐1.14)  0.69(0.02‐3.27)  0.38(0.01‐1.22)  0.1773  0.2956 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|g__Faecalibacterium|Other  0.00(0.00‐0.01)  0.01(0.00‐0.02)  0.00(0.00‐0.01)  0.1823  0.2976 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__|s__  0.00(0.00‐0.20)  0.00(0.00‐0.00)  0.00(0.00‐0.01)  0.1915  0.3065 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__coprophilus  0.06(0.00‐0.17)  0.04(0.01‐0.22)  0.06(0.00‐0.16)  0.2123  0.3331 
p__Proteobacteria|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__|s__  0.00(0.00‐0.03)  0.00(0.00‐0.01)  0.00(0.00‐0.02)  0.2191  0.3371 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Epulopiscium|s__  0.00(0.00‐0.01)  0.00(0.00‐0.72)  0.00(0.00‐0.08)  0.2245  0.3388 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|Other|Other  0.66(0.00‐2.31)  0.84(0.20‐6.18)  0.55(0.15‐3.00)  0.2431  0.3601 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Lachnospiraceae|g__Roseburia|s__  0.00(0.00‐0.01)  0.01(0.00‐0.03)  0.00(0.00‐0.01)  0.2569  0.3736 
p__Firmicutes|c__Erysipelotrichi|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Allobaculum|s__  0.72(0.18‐18.34)  0.35(0.08‐12.81)  1.21(0.09‐10.05)  0.2658  0.3756 
p__Fusobacteria|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__  22.11(0.21‐32.09)  15.31(12.18‐30.46)  21.27(10.89‐37.49)  0.2676  0.3756 
p__Firmicutes|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__luteciae  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.2817  0.3886 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__copri  0.64(0.01‐4.18)  0.02(0.01‐4.85)  0.22(0.02‐2.30)  0.3037  0.4118 
p__Proteobacteria|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae|g__|s__  0.01(0.00‐0.09)  0.02(0.00‐0.13)  0.01(0.00‐0.05)  0.3096  0.4128 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|g__Clostridium|s__perfringens  0.05(0.00‐2.23)  0.16(0.03‐0.26)  0.07(0.01‐0.68)  0.3314  0.4347 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__[Odoribacteraceae]|g__Odoribacter|s__  0.00(0.00‐0.04)  0.00(0.00‐0.02)  0.00(0.00‐0.03)  0.3764  0.4857 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Ruminococcaceae|Other|Other  0.09(0.00‐0.29)  0.08(0.02‐0.14)  0.10(0.01‐0.18)  0.3906  0.4959 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Clostridiaceae|g__Clostridium|s__  0.19(0.00‐0.88)  0.29(0.03‐0.53)  0.24(0.05‐0.68)  0.4375  0.5393 
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Table 7. Continued. 
  median (minumum‐maximum)       
Taxa  Baseline  Cholestyramine  Washout  p‐value  q‐value 
p__Proteobacteria|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae|g__Anaerobiospirillum|s__  0.77(0.01‐1.50)  0.72(0.14‐3.89)  0.83(0.27‐2.46)  0.4382  0.5393 
p__Firmicutes|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__  1.75(0.05‐29.07)  9.36(0.32‐26.14)  3.34(0.41‐27.01)  0.4839  0.5865 
p__Actinobacteria|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Adlercreutzia|s__  0.01(0.00‐0.04)  0.00(0.00‐0.04)  0.00(0.00‐0.02)  0.5015  0.5988 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__plebeius  0.01(0.00‐0.03)  0.01(0.00‐0.07)  0.01(0.00‐0.02)  0.5784  0.6804 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__|g__|s__  0.00(0.00‐0.29)  0.00(0.00‐0.30)  0.00(0.00‐0.31)  0.6007  0.6964 
p__Actinobacteria|c__Actinobacteria|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__  0.00(0.00‐0.07)  0.00(0.00‐0.02)  0.00(0.00‐0.08)  0.6434  0.7353 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__uniformis  0.01(0.00‐0.12)  0.01(0.00‐0.11)  0.01(0.00‐0.16)  0.7459  0.8405 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Peptostreptococcaceae|g__|s__  0.34(0.00‐0.76)  0.32(0.08‐1.32)  0.40(0.16‐1.22)  0.7823  0.8595 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__|g__|s__  0.41(0.00‐0.73)  0.38(0.22‐0.64)  0.45(0.16‐1.11)  0.7959  0.8595 
p__Actinobacteria|c__Actinobacteria|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|Other  0.05(0.03‐10.49)  0.04(0.02‐6.40)  0.05(0.03‐13.22)  0.7976  0.8595 
p__Tenericutes|c__Mollicutes|o__Anaeroplasmatales|f__Anaeroplasmataceae|Other|Other  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.00(0.00‐0.01)  0.8058  0.8595 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__S24‐7|g__|s__  0.21(0.02‐3.61)  0.03(0.01‐2.49)  0.29(0.00‐1.52)  0.8251  0.8686 
p__Deferribacteres|c__Deferribacteres|o__Deferribacterales|f__Deferribacteraceae|g__Mucispirillum|s__schaedleri  0.01(0.00‐0.04)  0.00(0.00‐0.06)  0.02(0.00‐0.05)  0.8788  0.9131 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__[Mogibacteriaceae]|g__|s__  0.01(0.00‐0.04)  0.01(0.00‐0.07)  0.01(0.00‐0.03)  0.9213  0.9449 
p__Firmicutes|c__Clostridia|o__Clostridiales|f__Eubacteriaceae|g__Pseudoramibacter_Eubacterium|s__  0.00(0.00‐0.04)  0.00(0.00‐0.04)  0.00(0.00‐0.03)  0.9577  0.9698 
p__Bacteroidetes|c__Bacteroidia|o__Bacteroidales|f__[Paraprevotellaceae]|g__|s__  0.01(0.00‐0.04)  0.01(0.01‐0.08)  0.01(0.00‐0.02)  0.9828  0.9828 
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Discussion 
In this study, 12 healthy dogs were administered cholestyramine in their food once 
daily for a duration of two weeks. The fecal microbiome and bile acid profile were 
evaluated. When dogs received cholestyramine, there were significant increases in the 
fecal concentration of DCA, secondary fUBA, and total fUBA. When measured as a 
percent of total fUBA, LCA significantly decreased while DCA significantly increased 
while dogs were on cholestyramine.  
 There were significant shifts in microbial communities based on both beta 
diversity metrics. No significant changes were noted for species richness between the 
groups. Univariate statistics identified a multitude of significant differences in bacterial 
abundances after adjusting for multiple comparisons.  
 A previous study showed that the sum of DCA, CDCA, and CA excretion increases 
with administration of cholestyramine in a dose dependent fashion up to 6 grams per day 
(i.e., 446 mg of bile acids/day) (Jansen and Zanetti, 1965). The main goal of that study 
was to investigate dose and resin particulate size and its ability reduce plasma cholesterol 
in healthy patients as it may pertain to patients suffering from coronary heart disease. That 
study reported that plasma cholesterol increased as resin doses increased from 1 to 3, 6, 
and 10 gm/dog/day.  Other studies evaluating the effects of cholestyramine on dogs have 
used similar dosage strategies as that in the present study (i.e., 0.7 g/kg) and provides 
sufficient evidence that this dosing strategy is likely to be safe and efficacious in eliciting 
systemic changes in dogs when administering cholestyramine (Gans and Cater, 1971). In 
dogs, cholestyramine has also been used to treat cyanobacterial (microcystin) toxicosis 
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(dose:  172 mg/kg q 24 h) (Rankin et al., 2013). The findings of the current study are 
similar to the study described previously in dogs fed cholestyramine.   
 Cholestyramine as a bile acid sequestrant has been utilized and is efficacious in 
managing primary bile acid diarrhea which occurs in approximately 32% of patients with 
diarrhea predominant IBS and general chronic GI disease (Wedlake et al., 2009). Bile acid 
diarrhea can be diagnosed by the serum C4 test or SeHCAT retention test, and by clinical 
response to bile acid sequestrants (Vijayvargiya et al., 2013). Bile acid dysmetabolism is 
prevalent in a subset of dogs with CE. Anecdotal evidence suggest that some dogs with 
chronic diarrhea unresponsive to traditional therapy (e.g., antimicrobials, 
immunosuppressive drugs, and dietary trials) may respond to cholestyramine. 
 Unpublished data from our lab suggests that the fecal bile acid pool in a subset of 
canine patients with chronic diarrhea is comprised almost exclusively of fecal primary bile 
acids. In the present study, cholestyramine significantly increased the concentration of 
DCA in feces. Deoxycholic acid is found in the highest concentration in feces compared 
to the other bile acids measured. In patients with chronic diarrhea, primary bile acids are 
found to be in the highest concentration in feces and decreasing this concentration may be 
useful.  
 Cholestyramine has reportedly been useful in cases of Clostridium difficile 
infection (Moncino and Falletta, 1992). It is thought that the factor that allows for 
germination of Clostridium difficile spores is associated with bile salts thereby allowing 
cholestyramine to effectively promote inhibition thereof. Cholestyramine has also been 
shown to bind C. difficile toxins A and B in vitro (Taylor and Bartlett, 1980). 
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Cholestyramine is not the first method of therapeutics for this C. difficile infection as 
cholestyramine is thought to bind to Vancomycin, which is a commonly used 
antimicrobial for the first defense against C. difficile infection.  
 There is no available evidence in scientific literature that has yet to evaluate the 
effect of cholestyramine on the fecal microbiota. This study provides useful insight into 
understanding the effects of cholestyramine in the GIT given the importance of bile acids 
and microbiota in maintaining gut. In the current study, dogs fed cholestyramine had lower 
fecal scores (firmer stools) than controls (mean; p-value: 2.48 and 1.98, respectively; 
p=0.0028). Interestingly, the change in microbial communities (i.e., beta diversity) was 
not accompanied by a change in species richness (i.e., alpha diversity). Clostridium 
hiranonis was found to significantly decrease after cholestyramine administration. This 
interaction may be explained by the 7α-dehyxroxylating function that belongs to this 
organism which converts primary to secondary bile acids. This could suggest a lack of 
substrate availability for the organism and may explain the decreased proportion of C. 
hiranonis according to sequencing results (Kitahara et al., 2001). 
 The present study provides a foundation to understanding the effects of 
cholestyramine in healthy dogs which may later be useful in extrapolating these effects to 
dogs with chronic GI disease. This study is limited in that it did not explore varieties of 
dosage. This may be useful in future studies when evaluating if dogs with chronic GI 
disease may be able to benefit from cholestyramine administration.  
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CHAPTER VI  
CONCLUSIONS	
 CE in dogs encompasses a number of diseases that are idiopathic in nature, and 
therefore, difficult to diagnose. Current research in dogs with CE has focused on a number 
of components to explain and categorize these different disease phenotypes. The 
microbiome is an area of focus in dogs with CE as well as in humans with IBD. A 
microbial dysbiosis has been identified in dogs with CE and IBD and remains present even 
after months of therapy. Describing the intestinal microbiota on a phylogenetic level (e.g., 
using sequencing of 16S rRNA genes) does not provide information pertaining to the 
function of bacteria within the GI tract. Researchers are now using platforms such as gas 
or liquid chromatography coupled with mass spectrometry to assess metabolite profiles 
that can better describe functional aspects of the GI tract. An untargeted approach is 
beneficial in that it unbiasedly identifies and then calculates the relative abundance of 
metabolites in a given sample. A targeted approach has the benefit of selectively 
identifying compounds and measuring the actual concentration based on standard curves. 
Recently, in an unpublished pilot study, our laboratory acquired untargeted metabolomic 
data from the feces of healthy dogs and dogs with CE. Fecal bile acids were significantly 
altered in dogs with CE. Bile acids are being widely considered as an important regulator 
of host health, given that bile acids mechanisms contribute to obesity, glycemic control, 
and the treatment of recurrent Clostridium difficile infection in humans (Oduyebo and 
Camilleri, 2017). Recent evidence in people suggests that bile acid malabsorption can 
account for 30% of cases of chronic diarrhea.   
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These findings coupled with current literature describing bile acid dysmetabolism 
in a number of human diseases prompted further investigation into the role bile acids have 
in the GI tract in healthy dogs and dogs with CE. We developed an assay for fUBA that 
was precise and reproducible. Benefits for developing an in-house assay included the rapid 
identification and quantification of fUBA. A targeted assay requires less time data mining 
as opposed to untargeted metabolomics. The purpose of this assay was to validate our 
previous untargeted metabolomic data in dogs with CE in a larger sample size of new and 
well-characterized patients with CE. This assay was developed using known standards to 
accurately identify and quantify fUBA. The developed assay may be beneficial to 
clinicians in that it has a fast turn-around time (i.e., approximately 2 days) and requires a 
single fecal sample. Naturally passed fecal samples are inherently excellent candidates for 
diagnostic assays. Fecal samples are non-invasive to collect and provide a snapshot of 
upstream metabolic activity. Fecal samples can also be collected by patient’s owners in 
the comfort of their own home. This decreases the likelihood of the patient’s surroundings 
affecting systemic metabolic activity (i.e., stress and fear). The entire GI tract has 
influence over fecal output which also contributes to the quality of the sample. Pitfalls of 
fecal samples are that they are heterogeneous in composition and can often require 
multiple steps of isolation to generate an extract with few impurities. The assay described 
within this body of research was time efficient and required minimal isolation of bile acids 
from feces.  
Our study identified that dogs with CE had significantly decreased secondary 
fUBA. A variety of reports in humans had identified bile acid malabsorption either by 
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serum tests (C4) or by the radio labeled SeHCAT test (i.e., the gold standard for testing 
bile acid malabsorption). Recent literature by Duboc et al., demonstrated that patients with 
IBD have decreased proportions of secondary bile acids and increased proportions of 
primary bile acids. While we did not measure serum bile acids or use standardized tests 
for bile acid malabsoprtion, we were able to identify bile acid malabsorption in dogs with 
CE through measuring fecal bile acids. We measured fecal bile acids in a number of 
healthy dogs. Secondary fUBA are expected to be found almost completely in the colon 
because of bacterial deconjugation and dehydroxylation. Duboc et al., also measured 
conjugated BA in feces, which accounted for approximately 3% of bile acids in healthy 
human subjects and approximately 9% of bile acids in human patients with active IBD. 
Unfortunately, our assay was unable to measure conjugated bile acids. An imbalance in 
secondary to primary fUBA may indicate a lack of bile acid absorption as well as microbial 
imbalance for those microbes responsible for this conversion. Most healthy dogs had 
between 90-100% secondary fUBA.  
It was evident that the fecal bile acid profile may be impacted long term by 
antibiotic administration. Many dogs that were considered clinically healthy but had 
received antibiotics within two weeks prior to sample collection had a fecal bile acid 
profile almost completely absent of secondary fUBA. It is possible that antibiotic 
administration or microbial dysbiosis weeks or maybe even months to years before fecal 
collection may cause residual decreased secondary fUBA proportions in otherwise 
clinically healthy dogs.  A proposed reference interval for the proportion of secondary 
fUBA was created for healthy dogs. Twenty out of 34 dogs with CE had a proportion of 
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secondary fUBA outside of the reference interval. The proportion of secondary fUBA 
significantly increased in patients with CE that were treated with immunosuppressive 
therapy over time and fUBA profiles returned within the reference interval described for 
the proportion of secondary fUBA. In the future, a new cohort of healthy dogs should be 
carefully screened and the sample size should be increased to validate the reference 
interval for healthy dogs in this study. Decreased proportions of secondary fUBA in dogs 
with CE was counteracted by increased CA in the feces of dogs with CE. It is unclear if 
increased CA or decreased presence of secondary fUBA is a driver of clinical signs of GI 
disease. UDCA and LCA have been established as having anti-inflammatory and 
cytoprotective effects in the colon, which may suggest the latter (Ward et al., 2017).  
Bile acid receptors such as the farnesoid X receptor may be an area of therapeutic 
manipulation since it is a key regulator of bile acid synthesis found in both the enterocytes 
and hepatocytes. When activated, it inhibits the transcription of genes that participate in 
bile acid synthesis. When activated in enterocytes, it is an agonist for fibroblast growth 
factor 19 which in turn navigates to the hepatocytes closing the negative feedback loop 
(Pavlidis et al., 2015).  
Characterizing the fecal bile acid profile in dogs with CE prompts further 
questioning in how clinicians may implement this knowledge in practice. The microbiome 
and fecal bile acid profile was evaluated in healthy dogs administered cholestyramine. 
Cholestyramine is a bile acid sequestrant well-known for its ability to mitigate bile acid 
diarrhea in human patients. Secondary fUBA increased after cholestyramine 
administration. Dogs with CE have long been treated using a variety of different 
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approaches including antimicrobials, food trials, and immunosuppressive drugs. Empirical 
treatment of CE using these methods however, can cause antibiotic induced microbial 
dysbiosis and immunosuppressive therapy can weaken the patient’s immune system and 
subsequently becoming less resistant to infection. Cholestyramine may be a candidate for 
therapeutic management of chronic canine GI disease. Cholestyramine could two-fold 
increase our level of understanding and care for patients with CE by 1) treating and 
properly identifying the underlying cause of GI clinical signs and disease and 2) 
potentially avoid side effects of other commonly used modes of therapy.  
While we did not trial cholestyramine in dogs with CE we would likely expect a 
different outcome than what was observed in healthy dogs. In dogs that received 
cholestyramine the concentration of DCA was found to be increased. DCA is also the most 
predominant fUBA identified in the feces of healthy dogs so it makes sense that 
cholestyramine primarily affects this compound. In patients with CE, our aim may be to 
restore the fecal bile acid profile to that of healthy dogs (i.e., mostly secondary fUBA). If 
we were to expect cholestyramine to have the greatest effect on the most predominant 
fUBA in dogs with CE then we might expect CA to be significantly altered. This may not 
be so simple, however, since some literature suggests cholestyramine binds preferentially 
to DCA and CDCA. In this scenario, other bile acid sequestrants should be trialed. 
  An inherent difficulty in understanding the underlying etiology behind CE in dogs 
is that patients are lost to follow-up. Long term outcome measures can help to establish 
whether certain serological or fecal markers are prognostic of positive or negative 
outcomes after months or years of treatment. In this collection of research, an untargeted 
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metabolomics approach was used to characterize the feces of dogs with IBD. This analysis 
revealed little overlap between healthy dogs and dogs with IBD at baseline according to 
95% confidence intervals. Over the course of treatment and after 1 year later, the 95% 
confidence interval of dogs with IBD began to share considerable more overlap with 
healthy dogs. Amino acids were identified as being significantly different between healthy 
dogs and dogs with IBD sampled at baseline, 3 weeks post therapy, 8 weeks post therapy, 
and more than 1 year after therapy. Almost 100 additional compounds were found to be 
significantly altered between the sample groups. This study suggests that there are many 
more changes occurring in the feces of dogs with IBD than simply changes in bile acid 
metabolism. Nevertheless, fecal bile acid dysmetabolism in dogs with CE is clearly 
evident and likely a major player in disease etiology at least in a subset of dogs. Studies 
using fecal microbial transplantation in humans with Clostridium difficile infection are 
now providing some of the most supportive evidence behind the importance of 
maintaining normal bile acid metabolism in the GI tract. Many patients with C. diff.  
infection also have bile acid dysmetabolism and clinical symptoms that can be ameliorated 
by fecal microbial transplantation.  
 In summary, a fecal bile acid dysmetabolism was reported in dogs with CE. This 
is characterized by a decrease in the percent of fUBA in dogs with CE. Cholestyramine, 
is effective in modulating the fecal bile acid composition and microbial community in 
healthy dogs and may be effective in treating those dogs with CE that fall outside of the 
reference interval described previously. These studies support the need for further 
investigation of bile acids along the GI tract. Our lab is currently evaluating 
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cholestyramine as a therapeutic approach in treating dogs with CE as well as 
characterizing fecal bile acid profiles in dogs that are administered fecal microbial 
transplantation.  
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